Cas protein and use thereof

WO2024078645A3PCT designated stage expired Publication Date: 2024-11-07GUANGZHOU REFORGENE MEDICINE CO LTD +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/142927
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-12-28
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

The existing CRISPR-Cas system has problems with sensitivity and efficiency in identifying specific targets during the gene editing process, and it is difficult to adapt to diverse target nucleic acid sequences.

Method used

Provide Cas protein with specific amino acid sequence identity, which can form a complex with the guide polynucleotide, specifically bind and cleave target DNA, recognize a variety of PAM sequences, and retain the function of the original Cas protein.

Benefits of technology

It improves the recognition sensitivity and efficiency of Cas protein in gene editing, adapts to diverse target sites, and enhances complementarity and cutting ability with guide polynucleotides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

Provided are a Cas protein and the use thereof. The amino acid sequence of the Cas protein comprises or is an amino acid sequence having at least 50% identity to any one of SEQ ID NOs: 1-461. Further provided are a guide polynucleotide, a Cas protein inactivating variant, a fusion protein or conjugate comprising the Cas protein, an isolated nucleic acid, a CRISPR-Cas protein system, a vector system, a delivery system, a cell, a pharmaceutical composition and a kit, and the uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Cas proteins and their applications Technical Field

[0001] The present disclosure relates to the field of CRISPR gene editing, and in particular to Cas proteins and their applications. Background Art

[0002] The CRISPR-Cas system is an adaptive immune defense developed by bacteria and archaea over a long period of evolution, used to combat invading viruses and foreign DNA. The clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein system (CRISPR-Cas system) allows for the rapid and effective alteration, modification, or regulation of gene sequences directly within cells.

[0003] Many researchers in this field are committed to finding new Cas proteins and CRISPR-Cas protein gene editing systems.

[0004] Summary of the Invention

[0005] The present invention provides Cas proteins and applications thereof.

[0006] In one aspect, the present invention provides a technical solution: a Cas protein, wherein the amino acid sequence of the Cas protein comprises or is an amino acid sequence having at least 50% identity with any one of SEQ ID NOs: 1-461.

[0007] The sequence table lists the Cas proteins with sequences of SEQ ID NOs: 1-461, the direct repeat sequences corresponding to all Cas proteins (SEQ ID NOs: 462-922), and the tracrRNA sequences corresponding to some Cas proteins (SEQ ID NOs: 923-1183).

[0008] In specific embodiments of the invention, the at least 50% identity is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identity.

[0009] In a specific embodiment of the invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to any one of SEQ ID NOs: 1-461.

[0010] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 80% identical to any one of SEQ ID NOs: 1-461.

[0011] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 85% identical to any one of SEQ ID NOs: 1-461.

[0012] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 1-461.

[0013] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 1-461.

[0014] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 97% identical to any one of SEQ ID NOs: 1-461.

[0015] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 98% identical to any one of SEQ ID NOs: 1-461.

[0016] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 99% identical to any one of SEQ ID NOs: 1-461.

[0017] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 99.5% identical to any one of SEQ ID NOs: 1-461.

[0018] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 99.7% identical to any one of SEQ ID NOs: 1-461.

[0019] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 99.8% identical to any one of SEQ ID NOs: 1-461.

[0020] In a specific embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence that is 100% identical to any one of SEQ ID NOs: 1-461.

[0021] In a specific embodiment of the present invention, the Cas protein retains the function of the protein shown in any one of SEQ ID NOs: 1-461.

[0022] In a specific embodiment of the present invention, the Cas protein can form a complex with a guide polynucleotide. In a specific embodiment of the present invention, the Cas protein can specifically bind to a target nucleic acid with a guide polynucleotide.

[0023] In a specific embodiment of the present invention, the Cas protein can form a complex with the guide polynucleotide, and the complex can specifically bind to the target nucleic acid. In a specific embodiment of the present invention, the Cas protein can form a complex with the guide polynucleotide, and the complex can specifically bind to the target DNA.

[0024] In a specific embodiment of the present invention, the Cas protein can specifically bind to the guide polynucleotide and cut the target nucleic acid. In a specific embodiment of the present invention, the Cas protein can specifically bind to the guide polynucleotide and cut the target DNA. In a specific embodiment of the present invention, the Cas protein can form a complex with the guide polynucleotide, and the complex can specifically bind to and cut the target nucleic acid. In a specific embodiment of the present invention, the Cas protein can form a complex with the guide polynucleotide, and the complex can specifically bind to and cut the target DNA.

[0025] In the present invention, retaining the function of the protein as shown in any one of SEQ ID NOs: 1-461 refers to retaining the ability to form a complex with a guide polynucleotide, retaining the ability to bind to a target nucleic acid complementary to the guide sequence of the guide polynucleotide, retaining the ability to target and cleave the target nucleic acid with the guide polynucleotide, and / or retaining the ability to process an RNA transcript comprising a guide sequence into a guide polynucleotide molecule.

[0026] In a specific embodiment of the present invention, the function of the protein represented by any one of SEQ ID NOs: 1-461 is retained, which is the ability to form a complex with a guide polynucleotide.

[0027] In a specific embodiment of the present invention, the function of the protein represented by any one of SEQ ID NOs: 1-461 is retained to be able to bind to a target nucleic acid complementary to the guide sequence of the guide polynucleotide.

[0028] In a specific embodiment of the present invention, the function of retaining the protein shown in any one of SEQ ID NOs: 1-461 is to retain and direct the ability of the polynucleotide to target and cleave the target nucleic acid.

[0029] In a specific embodiment of the present invention, the function of the protein represented by any one of SEQ ID NOs: 1-461 is retained to process the RNA transcript comprising the guide sequence into a guide polynucleotide molecule.

[0030] In a preferred embodiment of the present invention, the amino acid sequence of the Cas protein comprises or is an amino acid sequence as shown in any one of SEQ ID NOs: 1-461.

[0031] In a specific embodiment of the present invention, the PAM sequence (5'→3') recognizable by the Cas protein is selected from any one or more of the following:

[0032] A, C, T, G,

[0033] TA, TC, GN, AA, AG, TG, AN, GG, CG, TN, NT, NG, GT, NA, CC, AC, GC, AT, CT, GA, TT, CN, NC, CA,

[0034] <h2 style=";text-align:left;direction:ltr">NTN, ANN, TTN, ATC, NAC, AGA, TGC, TCT, NGN, CGC, NTC, GCA, TCG, TTT, CCG, GGG, NAG, ACA, CGG, CNG, ACN, GTG, CNT, TTG, TCN, GGT, TNC, CCN, CGT, TGG, CGA, NGG, TCC, AGT, NCA, CAN, TCA, NNG, TAC, CCT, NTG, CGN, TGN, CAT, NGC GNG, GNC, NNA, GAA, TTC, CTT, ATA, TAT, GCT, NCC, TTA, AGN, GNN, CAA, CAC, AGG, NTT, ANG, GNA, GTT, NGA, TAA, GTA, GGN, GNT, NCG, ATT, CCA, CNN, AAA, AAC, ATN, GAG, CTG, ACG, NAA, TAN, NAT, CNA, GCN, GTC, NCN, CTN, CNC, ANT, NNC, CAG, NAN, ATG, NCT, CCC, AAN, TGT, TNA, ACC, GAT, ACT, AAT, GGA, GAN, ANC, GAC, NNT, CTA, TNN, GCG, GTN, TNT, AAG, TAG, NGT, NTA, ANA, CTC, GCC, TGA, GGC, AGC, TNG<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0035] <h2 style=";text-align:left;direction:ltr">NGAA、GANC、GCNC、NTNT、TGGG、AAGG、AAGN、NTNN、TCGT、CNTG、NTGG、CCGN、AT AT、TGCA、NGGT、TGNT、NNTG、NCCG、ACAT、GNTG、CGCG、GACN、NTCG、TCNG、CTGC、 TNNC, GGTN, CGNN, TCCA, AGCN, TNAG, GGAC, GATC, AANA, NATG, CCAG, NAAT, TCNT, CACT, CGGC, CGAN, CNCA, ATNT, NNNG, NGCT, CTGG, GGAN, NTNC, ATTC, AATG CNTC、TGGN、NATC、GTCG、ACNC、GCNN、GACT、CTNT、NCTT、NAGG、NANC、CTTA、GT CT、ANAG、NGCN、CNNA、TCAG、ACAC、NCGG、TNNT、CAAG、ACCT、CCCA、GTNC、ANTC、 GACC、AACG、TTAA、TCCG、CGCC、NCCN、TTNA、NCNT、NGCA、AGNN、AATC、GGGA、GN AN、NAGA、CGNA、GTAT、GTNA、ATNC、ACNA、GGAA、NTCC、GGCG、AATN、CNNT、AGGC、 GCGN、GTGC、TTGA、AAGC、GAAG、ATNG、TGCT、TACT、CTAN、GGCT、GNGC、GTCN、CG AA、CNAC、GCCT、TAGG、ANGC、TNAA、GANT、NCNA、NCCT、AGAN、GTAA、TTTN、ATGA、 TGNA,CANC,ACGA,CCAC,CCGG,CTNG,CNGN,GGTA,NGNC,GTTT,CTAA,TNCT,CTGN,NGAC,TGTA,TANN,GCNT,GCTC,CNCG,AAAN,CCNT,GANA,CACA,CTNA,ANTN, TTNT, CCTG, TNTT, CANA, NTAN, CACG, GGAT, TTTC, GNCG, TACA, GTAC, GAGC, ACNN, ATGG, AANT, ATCC, ACCG, AGNC, TGTT, NCAT, ATTA, GNTT, GAGN, TNAC, GCCG NTNG,GTGG,GNGN,ACCA,NTAA,ACTN,NCTG,NCTA,TTTT,GCNG,NTAG,CAAA,GGNA,CNTN,TTAG,TCTG,NCTN,TATG,GCGT,TANT,GGGT,NACN,ACTG,CCNG,GNNT<h2 style=";text-align:left;direction:ltr">CCAT, GNTA, NANT, TACN, TGTN, ATCT, NCAN, TNGG, CNNN, AAGT, ATTN, GGNN, CAGC, CGTN, GCCC, GCTT, CNAT, NANA, CCNN, GNGA, TNGN, GCAG, CGNG, CCTT NGAG、NCNG、AANG、GGTC、ACTC、TGAA、NAGN、NNCA、ACGG、TGAC、TCCN、ANNN、 TCGN、TAAN、CAGG、TTAN、NGAN、NTGC、CCNC、TNTN、ATGN、GTGN、GCAT、NNGN、 NNCC, CCNA, CNAG, GNAC, CGNT, TTCN, TAGN, ANCT, NATN, GTGA, TNGT, CTAT, CCCG, TNCA, NGTA, NNGA, CGTG, TAAT, CGCA, NNCG, NGTC, NAGT, GNAT, TNTC NCGC, NGGN, CATN, GTTN, AGTA, GNNG, TTNN, TGNC, NAAA, TNCC, CACC, CTCT, TTGN, GCTA, NTTT, TGAN, TNAN, NGAT, CCTN, GAAT, GTCA, NTCN, GCCA, ANTG TGGC, CAAC, TTTA, TGTC, CGGA, NCGN, AGNT, NCGA, ANCG, ACAA, TAGT, CGAG, NCAA, AATA, AGGG, GNGT, CAGA, AGGT, GGGG, ANAC, TGGT, GTGT, GNCA, GTTA, NGTT, TNNG, NCAG、CACN、GCAN、GAAC、NCCA、TTCC、NCNN、GNNN、ANGT、NTNA、CCCT、GNAA、TTNG、 GTNN、GGNG、TCTA、NCAC、GANG、TTCG、CCTC、CNGG、ANNA、TCAN、ATCG、NTGA、CGTA、 TTAC, GCTN, GCTG, NGTG, TCCC, CANN, NNNA, TAGA, ACGT, AGAT, GATG, GCCN, TGNG, GCGC, CCGA, GNCN, NTTG, NNAT, TNCG, NANG, GGTG, NCCC, GNCC, CAAT, CGCN, CNGA NTTC, TTCT, NGGA, AGTC, CNNC, NACG, AGTN, NANN, ACAG, GNCT, TACC, CNTA, TGTG, CATC, GACA, TCTT, NTCT, CTGA, AGGA, GATA, TNAT, CCTA, GGAG, ANCC, AANC, GTAN<h2 style=";text-align:left;direction:ltr">GCNA, TGNN, TANC, GNTN, AGCG, CTAG, NNAA, AGTT, CTAC, TACG, TTNC, TNTA, ANTT, ATAC, TCCT, TCAC, NGGC, NTTN, NNTC, CANT, ATAA, TGCC, CTCC, TNNA, GTNG ACGN、GGCA、AAAG、TTGT、NGNA、NAAN、TATN、CGGG、CATA、ATGC、ACGC、ACCN、AT TT、TCNA、TNGC、NACA、NACC、CTCN、GGCC、TANG、AGAA、TNGA、TAGC、CAGN、GGCN、 ANNT, NNNC, TCAT, CATT, TAAA, ATGT, TGAG, CGCT, TCGG, GCAC, GTAG, NTCA, NATT, ANTA, CCCN, ACTA, AAAA, GAAN, TATT, NNAC, TGAT, GGGN, CCAA, GNGG, CCAN GTCC, NNCT, AGNG, CNTT, CNCT, GANN, GGTT, AGCT, CATG, NTAC, TNCN, NNTN, TGGA, GATT, AGCA, TAAG, GCGA, ACTT, ANGN, NTGN, AACN, AACT, TCAA, NTAT, TCGA NCTC, NNGG, ANGG, NNTT, GTNT, CTNN, CGGN, TAAC, GGNC, GAAA, ACNG, GNAG, TTGG, CTTC, CNGT, TNNN, TNTG, GTTG, TCNN, CGGT, GAGA, CNNG, NCNC, GAGG, AGCC ATNN、NNNT、AGAC、AACC、ANNC、ANNG、ACAN、GTTC、TATA、GNTC、NCGT、NGNT、CG TC、CCGC、CGAC、GACG、ATTG、GNNC、CNAA、TATC、AGNA、CTNC、TTCA、ANCA、ACCC、 AGTG、CCGT、ANAT、CTGT、GGGC、NTTA、NAAG、AANN、CNAN、NNCN、ANAA、ANAN、CT TG、NGNN、AGAG、TANA、TCNC、GCAA、NGNG、NAGC、NATA、ATCN、CGTT、CNGC、GATN、 NNTA,AAGA,CTTT,AAAC,AGGN,ACNT,NTGT,CTTN,ATCA,NACT,NNAG,NGTN,NAAC,TGCG,GGNT,ATAN,TTGC,ANCN,CCCC,ANGA,NGCG,TCTC,CTCG,ATNA,AATT,NNAN, NNGT, TCGC, ATAG, CAAN, AACA, TTAT, CAGT, GNNA, TGCN, GCGG, NGGG, CANG, TTTG, GAGT, AAAT, CTCA, CNCN, CNCC, TCTN, CGNC, NGCC, CGAT, NNGC;,

[0036] The N is A, T, C or G.

[0037] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of A.

[0038] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of C.

[0039] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of T.

[0040] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of G.

[0041] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TA-3'.

[0042] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TC-3'.

[0043] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GN-3'.

[0044] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AA-3'.

[0045] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AG-3'.

[0046] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TG-3'.

[0047] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AN-3'.

[0048] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GG-3'.

[0049] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CG-3'.

[0050] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TN-3'.

[0051] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NT-3'.

[0052] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NG-3'.

[0053] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GT-3'.

[0054] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NA-3'.

[0055] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CC-3'.

[0056] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AC-3'.

[0057] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GC-3'.

[0058] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AT-3'.

[0059] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CT-3'.

[0060] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GA-3'.

[0061] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TT-3'.

[0062] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CN-3'.

[0063] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NC-3'.

[0064] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CA-3'.

[0065] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTN-3'.

[0066] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANN-3'.

[0067] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTN-3'.

[0068] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATC-3'.

[0069] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAC-3'.

[0070] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-AGA-3'.

[0071] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGC-3'.

[0072] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCT-3'.

[0073] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGN-3'.

[0074] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGC-3'.

[0075] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTC-3'.

[0076] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCA-3'.

[0077] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCG-3'.

[0078] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTT-3'.

[0079] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCG-3'.

[0080] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGG-3'.

[0081] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAG-3'.

[0082] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACA-3'.

[0083] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGG-3'.

[0084] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNG-3'.

[0085] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACN-3'.

[0086] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTG-3'.

[0087] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNT-3'.

[0088] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTG-3'.

[0089] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCN-3'.

[0090] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGT-3'.

[0091] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNC-3'.

[0092] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCN-3'.

[0093] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGT-3'.

[0094] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TGG-3'.

[0095] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGA-3'.

[0096] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGG-3'.

[0097] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCC-3'.

[0098] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGT-3'.

[0099] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCA-3'.

[0100] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAN-3'.

[0101] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCA-3'.

[0102] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNG-3'.

[0103] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAC-3'.

[0104] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCT-3'.

[0105] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTG-3'.

[0106] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGN-3'.

[0107] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGN-3'.

[0108] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAT-3'.

[0109] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGC-3'.

[0110] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNG-3'.

[0111] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNC-3'.

[0112] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNA-3'.

[0113] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAA-3'.

[0114] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTC-3'.

[0115] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTT-3'.

[0116] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATA-3'.

[0117] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAT-3'.

[0118] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCT-3'.

[0119] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCC-3'.

[0120] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTA-3'.

[0121] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGN-3'.

[0122] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNN-3'.

[0123] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAA-3'.

[0124] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAC-3'.

[0125] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGG-3'.

[0126] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTT-3'.

[0127] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANG-3'.

[0128] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNA-3'.

[0129] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTT-3'.

[0130] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGA-3'.

[0131] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAA-3'.

[0132] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTA-3'.

[0133] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGN-3'.

[0134] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNT-3'.

[0135] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCG-3'.

[0136] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATT-3'.

[0137] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCA-3'.

[0138] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNN-3'.

[0139] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAA-3'.

[0140] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAC-3'.

[0141] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATN-3'.

[0142] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAG-3'.

[0143] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTG-3'.

[0144] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACG-3'.

[0145] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAA-3'.

[0146] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAN-3'.

[0147] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAT-3'.

[0148] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNA-3'.

[0149] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCN-3'.

[0150] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTC-3'.

[0151] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCN-3'.

[0152] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTN-3'.

[0153] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNC-3'.

[0154] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANT-3'.

[0155] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNC-3'.

[0156] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-CAG-3'.

[0157] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAN-3'.

[0158] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATG-3'.

[0159] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCT-3'.

[0160] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCC-3'.

[0161] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAN-3'.

[0162] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGT-3'.

[0163] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNA-3'.

[0164] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACC-3'.

[0165] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAT-3'.

[0166] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACT-3'.

[0167] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAT-3'.

[0168] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGA-3'.

[0169] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAN-3'.

[0170] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANC-3'.

[0171] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GAC-3'.

[0172] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNT-3'.

[0173] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTA-3'.

[0174] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNN-3'.

[0175] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCG-3'.

[0176] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTN-3'.

[0177] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNT-3'.

[0178] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAG-3'.

[0179] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAG-3'.

[0180] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGT-3'.

[0181] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTA-3'.

[0182] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANA-3'.

[0183] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTC-3'.

[0184] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCC-3'.

[0185] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGA-3'.

[0186] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGC-3'.

[0187] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-AGC-3'.

[0188] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNG-3'.

[0189] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTTA-3'.

[0190] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTTC-3'.

[0191] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTTG-3'.

[0192] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTTN-3'.

[0193] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGAA-3'.

[0194] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GANC-3'.

[0195] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCNC-3'.

[0196] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTNT-3'.

[0197] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGGG-3'.

[0198] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAGG-3'.

[0199] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAGN-3'.

[0200] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTNN-3'.

[0201] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCGT-3'.

[0202] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNTG-3'.

[0203] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTGG-3'.

[0204] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCGN-3'.

[0205] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATAT-3'.

[0206] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TGCA-3'.

[0207] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGGT-3'.

[0208] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGNT-3'.

[0209] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNTG-3'.

[0210] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCCG-3'.

[0211] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACAT-3'.

[0212] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNTG-3'.

[0213] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGCG-3'.

[0214] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GACN-3'.

[0215] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTCG-3'.

[0216] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCNG-3'.

[0217] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTGC-3'.

[0218] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNNC-3'.

[0219] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGTN-3'.

[0220] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-CGNN-3'.

[0221] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCCA-3'.

[0222] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGCN-3'.

[0223] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNAG-3'.

[0224] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GGAC-3'.

[0225] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GATC-3'.

[0226] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AANA-3'.

[0227] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NATG-3'.

[0228] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCAG-3'.

[0229] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAAT-3'.

[0230] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCNT-3'.

[0231] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-CACT-3'.

[0232] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-CGGC-3'.

[0233] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGAN-3'.

[0234] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNCA-3'.

[0235] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATNT-3'.

[0236] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNNG-3'.

[0237] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGCT-3'.

[0238] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTGG-3'.

[0239] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGAN-3'.

[0240] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-NTNC-3'.

[0241] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATTC-3'.

[0242] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AATG-3'.

[0243] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNTC-3'.

[0244] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGGN-3'.

[0245] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NATC-3'.

[0246] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTCG-3'.

[0247] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACNC-3'.

[0248] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCNN-3'.

[0249] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GACT-3'.

[0250] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTNT-3'.

[0251] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCTT-3'.

[0252] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAGG-3'.

[0253] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NANC-3'.

[0254] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTTA-3'.

[0255] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTCT-3'.

[0256] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANAG-3'.

[0257] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGCN-3'.

[0258] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNNA-3'.

[0259] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCAG-3'.

[0260] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACAC-3'.

[0261] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCGG-3'.

[0262] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNNT-3'.

[0263] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAAG-3'.

[0264] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACCT-3'.

[0265] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCCA-3'.

[0266] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GTNC-3'.

[0267] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANTC-3'.

[0268] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GACC-3'.

[0269] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AACG-3'.

[0270] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTAA-3'.

[0271] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCCG-3'.

[0272] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGCC-3'.

[0273] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCCN-3'.

[0274] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTNA-3'.

[0275] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCNT-3'.

[0276] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGCA-3'.

[0277] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGNN-3'.

[0278] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AATC-3'.

[0279] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGGA-3'.

[0280] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNAN-3'.

[0281] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAGA-3'.

[0282] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGNA-3'.

[0283] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTAT-3'.

[0284] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTNA-3'.

[0285] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATNC-3'.

[0286] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACNA-3'.

[0287] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGAA-3'.

[0288] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTCC-3'.

[0289] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGCG-3'.

[0290] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AATN-3'.

[0291] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNNT-3'.

[0292] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGGC-3'.

[0293] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCGN-3'.

[0294] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTGC-3'.

[0295] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TTGA-3'.

[0296] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAGC-3'.

[0297] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAAG-3'.

[0298] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATNG-3'.

[0299] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TGCT-3'.

[0300] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TACT-3'.

[0301] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTAN-3'.

[0302] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-GGCT-3'.

[0303] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNGC-3'.

[0304] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTCN-3'.

[0305] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGAA-3'.

[0306] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNAC-3'.

[0307] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCCT-3'.

[0308] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAGG-3'.

[0309] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANGC-3'.

[0310] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNAA-3'.

[0311] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GANT-3'.

[0312] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCNA-3'.

[0313] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCCT-3'.

[0314] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGAN-3'.

[0315] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTAA-3'.

[0316] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTTN-3'.

[0317] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-ATGA-3'.

[0318] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGNA-3'.

[0319] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CANC-3'.

[0320] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACGA-3'.

[0321] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCAC-3'.

[0322] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCGG-3'.

[0323] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTNG-3'.

[0324] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNGN-3'.

[0325] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGTA-3'.

[0326] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGNC-3'.

[0327] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTTT-3'.

[0328] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTAA-3'.

[0329] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNCT-3'.

[0330] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTGN-3'.

[0331] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGAC-3'.

[0332] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGTA-3'.

[0333] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TANN-3'.

[0334] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCNT-3'.

[0335] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCTC-3'.

[0336] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNCG-3'.

[0337] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAAN-3'.

[0338] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCNT-3'.

[0339] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GANA-3'.

[0340] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CACA-3'.

[0341] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTNA-3'.

[0342] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANTN-3'.

[0343] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTNT-3'.

[0344] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCTG-3'.

[0345] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNTT-3'.

[0346] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CANA-3'.

[0347] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTAN-3'.

[0348] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CACG-3'.

[0349] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGAT-3'.

[0350] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTTC-3'.

[0351] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNCG-3'.

[0352] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TACA-3'.

[0353] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTAC-3'.

[0354] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAGC-3'.

[0355] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACNN-3'.

[0356] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-ATGG-3'.

[0357] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AANT-3'.

[0358] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATCC-3'.

[0359] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACCG-3'.

[0360] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGNC-3'.

[0361] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGTT-3'.

[0362] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCAT-3'.

[0363] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATTA-3'.

[0364] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNTT-3'.

[0365] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAGN-3'.

[0366] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNAC-3'.

[0367] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GCCG-3'.

[0368] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTNG-3'.

[0369] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GTGG-3'.

[0370] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNGN-3'.

[0371] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACCA-3'.

[0372] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTAA-3'.

[0373] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACTN-3'.

[0374] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCTG-3'.

[0375] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCTA-3'.

[0376] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTTT-3'.

[0377] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCNG-3'.

[0378] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTAG-3'.

[0379] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAAA-3'.

[0380] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGNA-3'.

[0381] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNTN-3'.

[0382] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TTAG-3'.

[0383] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCTG-3'.

[0384] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCTN-3'.

[0385] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TATG-3'.

[0386] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCGT-3'.

[0387] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TANT-3'.

[0388] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGGT-3'.

[0389] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NACN-3'.

[0390] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACTG-3'.

[0391] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCNG-3'.

[0392] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNNT-3'.

[0393] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-CCAT-3'.

[0394] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNTA-3'.

[0395] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NANT-3'.

[0396] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TACN-3'.

[0397] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGTN-3'.

[0398] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATCT-3'.

[0399] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCAN-3'.

[0400] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNGG-3'.

[0401] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNNN-3'.

[0402] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAGT-3'.

[0403] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATTN-3'.

[0404] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-GGNN-3'.

[0405] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAGC-3'.

[0406] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGTN-3'.

[0407] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCCC-3'.

[0408] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCTT-3'.

[0409] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNAT-3'.

[0410] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NANA-3'.

[0411] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCNN-3'.

[0412] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNGA-3'.

[0413] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNGN-3'.

[0414] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GCAG-3'.

[0415] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGNG-3'.

[0416] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCTT-3'.

[0417] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGAG-3'.

[0418] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCNG-3'.

[0419] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-AANG-3'.

[0420] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGTC-3'.

[0421] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACTC-3'.

[0422] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGAA-3'.

[0423] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAGN-3'.

[0424] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNCA-3'.

[0425] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACGG-3'.

[0426] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGAC-3'.

[0427] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCCN-3'.

[0428] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANNN-3'.

[0429] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCGN-3'.

[0430] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAAN-3'.

[0431] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAGG-3'.

[0432] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTAN-3'.

[0433] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGAN-3'.

[0434] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTGC-3'.

[0435] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCNC-3'.

[0436] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNTN-3'.

[0437] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATGN-3'.

[0438] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTGN-3'.

[0439] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCAT-3'.

[0440] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNGN-3'.

[0441] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNCC-3'.

[0442] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCNA-3'.

[0443] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNAG-3'.

[0444] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNAC-3'.

[0445] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGNT-3'.

[0446] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TTCN-3'.

[0447] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAGN-3'.

[0448] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANCT-3'.

[0449] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NATN-3'.

[0450] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTGA-3'.

[0451] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNGT-3'.

[0452] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTAT-3'.

[0453] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCCG-3'.

[0454] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNCA-3'.

[0455] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGTA-3'.

[0456] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNGA-3'.

[0457] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGTG-3'.

[0458] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAAT-3'.

[0459] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGCA-3'.

[0460] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNCG-3'.

[0461] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGTC-3'.

[0462] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAGT-3'.

[0463] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNAT-3'.

[0464] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNTC-3'.

[0465] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCGC-3'.

[0466] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGGN-3'.

[0467] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CATN-3'.

[0468] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTTN-3'.

[0469] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGTA-3'.

[0470] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNNG-3'.

[0471] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTNN-3'.

[0472] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGNC-3'.

[0473] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAAA-3'.

[0474] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNCC-3'.

[0475] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CACC-3'.

[0476] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTCT-3'.

[0477] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTGN-3'.

[0478] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCTA-3'.

[0479] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTTT-3'.

[0480] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGAN-3'.

[0481] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNAN-3'.

[0482] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGAT-3'.

[0483] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCTN-3'.

[0484] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GAAT-3'.

[0485] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTCA-3'.

[0486] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTCN-3'.

[0487] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCCA-3'.

[0488] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANTG-3'.

[0489] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TGGC-3'.

[0490] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAAC-3'.

[0491] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTTA-3'.

[0492] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGTC-3'.

[0493] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGGA-3'.

[0494] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCGN-3'.

[0495] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGNT-3'.

[0496] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCGA-3'.

[0497] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-ANCG-3'.

[0498] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACAA-3'.

[0499] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAGT-3'.

[0500] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGAG-3'.

[0501] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCAA-3'.

[0502] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AATA-3'.

[0503] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGGG-3'.

[0504] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNGT-3'.

[0505] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAGA-3'.

[0506] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGGT-3'.

[0507] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGGG-3'.

[0508] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANAC-3'.

[0509] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGGT-3'.

[0510] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTGT-3'.

[0511] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNCA-3'.

[0512] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTTA-3'.

[0513] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGTT-3'.

[0514] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNNG-3'.

[0515] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCAG-3'.

[0516] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CACN-3'.

[0517] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCAN-3'.

[0518] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GAAC-3'.

[0519] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCCA-3'.

[0520] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTCC-3'.

[0521] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCNN-3'.

[0522] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNNN-3'.

[0523] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANGT-3'.

[0524] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTNA-3'.

[0525] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCCT-3'.

[0526] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNAA-3'.

[0527] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTNG-3'.

[0528] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-GTNN-3'.

[0529] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGNG-3'.

[0530] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCTA-3'.

[0531] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCAC-3'.

[0532] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GANG-3'.

[0533] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TTCG-3'.

[0534] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCTC-3'.

[0535] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNGG-3'.

[0536] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANNA-3'.

[0537] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCAN-3'.

[0538] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATCG-3'.

[0539] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTGA-3'.

[0540] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGTA-3'.

[0541] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTAC-3'.

[0542] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCTN-3'.

[0543] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GCTG-3'.

[0544] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGTG-3'.

[0545] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCCC-3'.

[0546] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CANN-3'.

[0547] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNNA-3'.

[0548] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAGA-3'.

[0549] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACGT-3'.

[0550] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGAT-3'.

[0551] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GATG-3'.

[0552] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCCN-3'.

[0553] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGNG-3'.

[0554] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCGC-3'.

[0555] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCGA-3'.

[0556] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNCN-3'.

[0557] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTTG-3'.

[0558] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNAT-3'.

[0559] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNCG-3'.

[0560] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-NANG-3'.

[0561] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGTG-3'.

[0562] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCCC-3'.

[0563] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNCC-3'.

[0564] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAAT-3'.

[0565] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGCN-3'.

[0566] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNGA-3'.

[0567] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTTC-3'.

[0568] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTCT-3'.

[0569] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGGA-3'.

[0570] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGTC-3'.

[0571] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNNC-3'.

[0572] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NACG-3'.

[0573] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGTN-3'.

[0574] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NANN-3'.

[0575] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACAG-3'.

[0576] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNCT-3'.

[0577] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TACC-3'.

[0578] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNTA-3'.

[0579] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TGTG-3'.

[0580] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CATC-3'.

[0581] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GACA-3'.

[0582] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCTT-3'.

[0583] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTCT-3'.

[0584] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTGA-3'.

[0585] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-AGGA-3'.

[0586] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GATA-3'.

[0587] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNAT-3'.

[0588] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCTA-3'.

[0589] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGAG-3'.

[0590] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANCC-3'.

[0591] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AANC-3'.

[0592] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTAN-3'.

[0593] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCNA-3'.

[0594] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGNN-3'.

[0595] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TANC-3'.

[0596] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNTN-3'.

[0597] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGCG-3'.

[0598] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTAG-3'.

[0599] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNAA-3'.

[0600] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGTT-3'.

[0601] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTAC-3'.

[0602] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TACG-3'.

[0603] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TTNC-3'.

[0604] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNTA-3'.

[0605] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANTT-3'.

[0606] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATAC-3'.

[0607] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCCT-3'.

[0608] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCAC-3'.

[0609] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGGC-3'.

[0610] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTTN-3'.

[0611] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNTC-3'.

[0612] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CANT-3'.

[0613] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATAA-3'.

[0614] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TGCC-3'.

[0615] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTCC-3'.

[0616] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNNA-3'.

[0617] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTNG-3'.

[0618] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACGN-3'.

[0619] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGCA-3'.

[0620] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAAG-3'.

[0621] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTGT-3'.

[0622] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGNA-3'.

[0623] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAAN-3'.

[0624] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TATN-3'.

[0625] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-CGGG-3'.

[0626] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CATA-3'.

[0627] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-ATGC-3'.

[0628] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-ACGC-3'.

[0629] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACCN-3'.

[0630] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATTT-3'.

[0631] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCNA-3'.

[0632] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNGC-3'.

[0633] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NACA-3'.

[0634] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NACC-3'.

[0635] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTCN-3'.

[0636] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGCC-3'.

[0637] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TANG-3'.

[0638] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGAA-3'.

[0639] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNGA-3'.

[0640] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAGC-3'.

[0641] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAGN-3'.

[0642] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGCN-3'.

[0643] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANNT-3'.

[0644] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNNC-3'.

[0645] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCAT-3'.

[0646] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CATT-3'.

[0647] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAAA-3'.

[0648] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATGT-3'.

[0649] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TGAG-3'.

[0650] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGCT-3'.

[0651] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCGG-3'.

[0652] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCAC-3'.

[0653] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTAG-3'.

[0654] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTCA-3'.

[0655] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NATT-3'.

[0656] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANTA-3'.

[0657] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCCN-3'.

[0658] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACTA-3'.

[0659] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAAA-3'.

[0660] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GAAN-3'.

[0661] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TATT-3'.

[0662] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNAC-3'.

[0663] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGAT-3'.

[0664] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGGN-3'.

[0665] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCAA-3'.

[0666] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNGG-3'.

[0667] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCAN-3'.

[0668] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTCC-3'.

[0669] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNCT-3'.

[0670] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGNG-3'.

[0671] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNTT-3'.

[0672] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNCT-3'.

[0673] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GANN-3'.

[0674] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGTT-3'.

[0675] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGCT-3'.

[0676] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CATG-3'.

[0677] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTAC-3'.

[0678] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNCN-3'.

[0679] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNTN-3'.

[0680] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGGA-3'.

[0681] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GATT-3'.

[0682] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGCA-3'.

[0683] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAAG-3'.

[0684] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCGA-3'.

[0685] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACTT-3'.

[0686] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANGN-3'.

[0687] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTGN-3'.

[0688] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AACN-3'.

[0689] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-AACT-3'.

[0690] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCAA-3'.

[0691] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTAT-3'.

[0692] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TCGA-3'.

[0693] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCTC-3'.

[0694] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNGG-3'.

[0695] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANGG-3'.

[0696] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNTT-3'.

[0697] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTNT-3'.

[0698] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTNN-3'.

[0699] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGGN-3'.

[0700] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TAAC-3'.

[0701] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGNC-3'.

[0702] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAAA-3'.

[0703] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACNG-3'.

[0704] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNAG-3'.

[0705] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTGG-3'.

[0706] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-CTTC-3'.

[0707] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNGT-3'.

[0708] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNNN-3'.

[0709] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TNTG-3'.

[0710] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTTG-3'.

[0711] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCNN-3'.

[0712] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGGT-3'.

[0713] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAGA-3'.

[0714] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNNG-3'.

[0715] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCNC-3'.

[0716] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAGG-3'.

[0717] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-AGCC-3'.

[0718] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATNN-3'.

[0719] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNNT-3'.

[0720] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGAC-3'.

[0721] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-AACC-3'.

[0722] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANNC-3'.

[0723] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANNG-3'.

[0724] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACAN-3'.

[0725] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GTTC-3'.

[0726] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TATA-3'.

[0727] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNTC-3'.

[0728] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NCGT-3'.

[0729] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGNT-3'.

[0730] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGTC-3'.

[0731] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCGC-3'.

[0732] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGAC-3'.

[0733] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-GACG-3'.

[0734] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATTG-3'.

[0735] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-GNNC-3'.

[0736] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNAA-3'.

[0737] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TATC-3'.

[0738] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGNA-3'.

[0739] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with the sequence 5'-CTNC-3'.

[0740] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTCA-3'.

[0741] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANCA-3'.

[0742] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACCC-3'.

[0743] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGTG-3'.

[0744] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCGT-3'.

[0745] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANAT-3'.

[0746] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTGT-3'.

[0747] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGGC-3'.

[0748] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTTA-3'.

[0749] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAAG-3'.

[0750] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AANN-3'.

[0751] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNAN-3'.

[0752] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNCN-3'.

[0753] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANAA-3'.

[0754] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANAN-3'.

[0755] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-CTTG-3'.

[0756] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGNN-3'.

[0757] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGAG-3'.

[0758] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TANA-3'.

[0759] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCNC-3'.

[0760] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCAA-3'.

[0761] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGNG-3'.

[0762] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAGC-3'.

[0763] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NATA-3'.

[0764] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATCN-3'.

[0765] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGTT-3'.

[0766] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNGC-3'.

[0767] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GATN-3'.

[0768] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNTA-3'.

[0769] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-AAGA-3'.

[0770] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTTT-3'.

[0771] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-AAAC-3'.

[0772] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AGGN-3'.

[0773] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ACNT-3'.

[0774] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NTGT-3'.

[0775] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CTTN-3'.

[0776] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATCA-3'.

[0777] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NACT-3'.

[0778] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNAG-3'.

[0779] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGTN-3'.

[0780] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NAAC-3'.

[0781] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-TGCG-3'.

[0782] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GGNT-3'.

[0783] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATAN-3'.

[0784] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTGC-3'.

[0785] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANCN-3'.

[0786] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CCCC-3'.

[0787] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ANGA-3'.

[0788] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGCG-3'.

[0789] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCTC-3'.

[0790] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-CTCG-3'.

[0791] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATNA-3'.

[0792] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AATT-3'.

[0793] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNAN-3'.

[0794] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NNGT-3'.

[0795] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCGC-3'.

[0796] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-ATAG-3'.

[0797] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAAN-3'.

[0798] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AACA-3'.

[0799] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTAT-3'.

[0800] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CAGT-3'.

[0801] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GNNA-3'.

[0802] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TGCN-3'.

[0803] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GCGG-3'.

[0804] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGGG-3'.

[0805] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CANG-3'.

[0806] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TTTG-3'.

[0807] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-GAGT-3'.

[0808] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-AAAT-3'.

[0809] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-CTCA-3'.

[0810] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNCN-3'.

[0811] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CNCC-3'.

[0812] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-TCTN-3'.

[0813] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGNC-3'.

[0814] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-NGCC-3'.

[0815] In a specific embodiment of the present invention, the Cas protein can recognize a PAM with a sequence of 5'-CGAT-3'.

[0816] In a specific embodiment of the present invention, the Cas protein can recognize a PAM sequence of 5'-NNGC-3'.

[0817] In some embodiments of the present invention, the Cas protein is an inactivated variant of the Cas protein. In some embodiments of the present invention, the inactivated variant of the Cas protein is a dead Cas protein or a nickase Cas protein.

[0818] In some embodiments of the present invention, the Cas protein is selected from the active fragments constituting any one of the Cas proteins of the present invention.

[0819] On the other hand, a technical solution provided by the present invention is: a guide polynucleotide comprising (i) a direct repeat sequence, wherein the direct repeat sequence has at least 50% identity with any one of SEQ ID NOs: 462-922, and (ii) a guide sequence engineered to hybridize with a target nucleic acid; the direct repeat sequence is connected to the guide sequence, and the guide polynucleotide is capable of forming a complex with the Cas protein and guiding the complex to bind specifically to the sequence of the target nucleic acid.

[0820] In some embodiments of the invention, the direct repeat sequence has at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity compared to any one of SEQ ID NOs: 462-922.

[0821] In some embodiments of the present invention, the same direction repeat sequence has at least 60% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the present invention, the same direction repeat sequence has at least 65% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the present invention, the same direction repeat sequence has at least 70% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the present invention, the same direction repeat sequence has at least 75% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the present invention, the same direction repeat sequence has at least 80% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the present invention, the same direction repeat sequence has at least 85% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the present invention, the same direction repeat sequence has at least 90% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the invention, the same direction repeat sequence has at least 95% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the invention, the same direction repeat sequence has at least 96% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the invention, the same direction repeat sequence has at least 97% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the invention, the same direction repeat sequence has at least 98% sequence identity compared to any one of SEQ ID NO: 462-922. In some embodiments of the invention, the same direction repeat sequence has 100% sequence identity compared to any one of SEQ ID NO: 462-922.

[0822] In a preferred embodiment, the Cas protein is the Cas protein described in the present invention.

[0823] In a specific embodiment of the invention, the guide sequence comprises 15-60 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-50 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-40 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-35 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-30 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-25 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 18-25 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 20-25 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 18-22 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 20-22 nucleotides. In specific embodiments of the invention, the guide sequence comprises 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.

[0824] In a specific embodiment of the invention, the guide sequence hybridizes to the target nucleic acid, and the guide sequence is 90%-100% complementary to the target nucleic acid.

[0825] In specific embodiments of the invention, the guide sequence hybridizes to the target nucleic acid.

[0826] In specific embodiments of the invention, the guide sequence hybridizes to the target nucleic acid, with no more than one nucleotide mismatch between the guide sequence and the target nucleic acid.

[0827] In a specific embodiment of the invention, the direct repeat sequence comprises 15-100 nucleotides. In a specific embodiment of the invention, the direct repeat sequence comprises 15-90 nucleotides. In a specific embodiment of the invention, the direct repeat sequence comprises 15-80 nucleotides. In a specific embodiment of the invention, the direct repeat sequence comprises 15-70 nucleotides. In a specific embodiment of the invention, the direct repeat sequence comprises 15-60 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-50 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-40 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 20-40 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 20-30 nucleotides. In specific embodiments of the invention, the guide sequence comprises 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 nucleotides.

[0828] In a specific embodiment of the invention, the guide sequence is located at the 3' end of the direct repeat sequence.

[0829] In a specific embodiment of the invention, the guide sequence is located at the 5' end of the direct repeat sequence.

[0830] In a specific embodiment of the invention, the guide polynucleotide further comprises a tracrRNA.

[0831] In some embodiments of the invention, the tracrRNA sequence has at least 50% identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the invention, the tracrRNA sequence has at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity compared to any one of SEQ ID NOs: 923-1183.

[0832] In some embodiments of the invention, the tracrRNA sequence has at least 60% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the invention, the tracrRNA sequence has at least 65% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the invention, the tracrRNA sequence has at least 70% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the invention, the tracrRNA sequence has at least 75% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the invention, the tracrRNA sequence has at least 80% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the invention, the tracrRNA sequence has at least 85% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the present invention, the tracrRNA sequence has at least 90% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the present invention, the tracrRNA sequence has at least 95% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the present invention, the tracrRNA sequence has at least 96% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the present invention, the tracrRNA sequence has at least 97% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the present invention, the tracrRNA sequence has at least 98% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the present invention, the tracrRNA sequence has 100% sequence identity compared to any one of SEQ ID NOs: 923-1183. In some embodiments of the present invention, the tracrRNA sequence is optionally selected from the sequence shown in any one of SEQ ID NOs: 923-1183.

[0833] In a specific embodiment of the present invention, the tracrRNA can be complementary to the direct repeat sequence. In general, the complementary pairing is a complementary pairing of partial bases. In a specific embodiment of the present invention, the tracrRNA can interact with the direct repeat sequence.

[0834] In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence through a nucleotide sequence. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence through a nucleotide sequence consisting of 1-10 nucleotides. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence through a nucleotide sequence consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence through a nucleotide sequence consisting of 4 nucleotides. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence through a 5'-GAAA-3' sequence.

[0835] In a specific embodiment of the present invention, the tracrRNA sequence is located at the 3' end of the direct repeat sequence.

[0836] In a specific embodiment of the present invention, the tracrRNA sequence is located at the 5' end of the direct repeat sequence.

[0837] In a specific embodiment of the invention, the tracrRNA comprises 10-200 nucleotides. In a specific embodiment of the invention, the tracrRNA comprises 10-190, 10-180, 10-170, 10-160, 10-150, 10-140, 10-130, 10-120, 10-110, 10-100, 10-90, 10-80, 10-70, 10-60, 10-50, 10- or 40, 10-30, 10-20, 10-100, 10-100, 10-100, 10-100, 10-100, 10-100, 20-100, 30-100, 40-100, 20-90, 20-80, 20-70, 20-60, 20-50, or 30-50 nucleotides. In a specific embodiment of the present invention, the tracrRNA comprises 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 94, 95, 96, 97, 98, 99, or 100 nucleotides.

[0838] The sequence listing shows the tracrRNA sequences corresponding to some Cas proteins. When the sequence listing does not list the tracrRNA sequence corresponding to a specific Cas protein, the corresponding gRNA may contain only the guide sequence and DR sequence, without the tracrRNA sequence. When the sequence listing lists the tracrRNA sequence corresponding to a specific Cas protein, the gRNA may or may not contain the tracrRNA sequence in addition to the guide sequence and DR sequence.

[0839] On the other hand, a technical solution provided by the present invention is: an inactivated variant of the Cas protein, characterized in that the inactivated variant of the Cas protein is a nuclease activity inactivated variant of the Cas protein as described in the present invention.

[0840] In a specific embodiment of the present invention, the inactivated variant of the Cas protein is a variant in which the nuclease activity is completely inactivated, i.e., a dead Cas protein inactivated variant (dCas protein). The dCas protein can only bind to the target nucleic acid under the mediation of the guide polynucleotide, and has no or almost no function of cutting the target nucleic acid. For example, the target nucleic acid cutting efficiency of the dCas protein is ≤20%, ≤15%, ≤10%, ≤5%, ≤4%, ≤3%, ≤2% or ≤1% of the target nucleic acid cutting efficiency of the Cas protein before the inactivation mutation.

[0841] In a specific embodiment of the present invention, the Cas protein inactivated variant is a variant with partially inactivated nuclease activity. Further, the variant with partially inactivated nuclease activity is a Cas protein nickase (nickase Cas protein, nCas protein), which binds to the target nucleic acid under the mediation of the guide polynucleotide and then cuts one of the single strands in the double-stranded target nucleic acid without cutting the other single strand.

[0842] In a preferred embodiment of the present invention, the inactivated variant of the Cas protein is an inactivated Ruvc domain of the Cas protein.

[0843] In a preferred embodiment of the present invention, the inactivated variant of the Cas protein is an inactivated Ruvc-I, Ruvc-II or Ruvc-III domain of the Cas protein.

[0844] In a preferred embodiment of the present invention, the inactivated variant of the Cas protein is obtained by introducing an inactivating mutation into the Ruvc-I, Ruvc-II or Ruvc-III domain of the Cas protein.

[0845] In a specific embodiment of the present invention, the PAM sequence that can be recognized by the inactivated variant of the Cas protein is the same as the PAM sequence that can be recognized by the Cas protein.

[0846] On the other hand, a technical solution provided by the present invention is: a fusion protein or conjugate, wherein the fusion protein or conjugate comprises the following elements: (1) the Cas protein as described in the present invention, or the inactivated variant of the Cas protein as described in the present invention; and (2) a homologous or heterologous functional domain.

[0847] In a specific embodiment of the present invention, a fusion protein is provided, which comprises: (1) the Cas protein as described in the present invention, or the inactivated variant of the Cas protein as described in the present invention; and (2) a homologous or heterologous functional domain.

[0848] In a specific embodiment of the present invention, a fusion protein is provided, which comprises: (1) the Cas protein as described in the present invention; and (2) a homologous or heterologous functional domain.

[0849] In a specific embodiment of the present invention, a conjugate is provided, which comprises: (1) the Cas protein as described in the present invention, or the inactivated variant of the Cas protein as described in the present invention; and (2) a homologous or heterologous functional domain.

[0850] In a specific embodiment of the present invention, a conjugate is provided, comprising: (1) the Cas protein as described in the present invention; and (2) a homologous or heterologous functional domain.

[0851] In a specific embodiment of the present invention, the homologous or heterologous functional domains are optionally selected from one or more of the following: subcellular localization signals, DNA binding domains, protease domains, transcription activation domains, transcription repression domains, nuclease domains, deaminase domains, uracil DNA glycosylase domains (UDG), uracil DNA glycosylase inhibitory domains (UGI), methylases, demethylases, transcription release factors, histone acetylase domains, histone deacetylase domains, DNA ligases, affinity tags, reporter tags, affinity domains and reporter domains.

[0852] In some embodiments of the present invention, the subcellular localization signal is selected from the group consisting of: a nuclear localization signal, a nuclear export signal, a mitochondrial localization signal, and a chloroplast localization signal.

[0853] In a specific embodiment of the present invention, the fusion protein or conjugate comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or more homologous or heterologous functional domains; the functional domains are the same or different.

[0854] In some embodiments, the fusion protein or conjugate is arbitrarily linked to 0, 1, 2, 3, 4, 5, 6, 7, 8 or more of the protein domains at the N-terminus and / or C-terminus of the Cas protein.

[0855] In a specific embodiment of the present invention, the fusion protein comprises 1, 2, 3, 4 or more nuclear localization signals.

[0856] In a specific embodiment of the present invention, the fusion protein can be used to achieve base editing, for example, in combination with a guide polynucleotide to achieve base editing. In a specific embodiment of the present invention, the fusion protein comprises a nuclear localization signal and a deaminase domain.

[0857] In a specific embodiment of the present invention, the fusion protein comprises a nuclear localization signal and a cytidine deaminase domain. The fusion protein can be used to achieve C→T base editing.

[0858] In a specific embodiment of the present invention, the fusion protein comprises a nuclear localization signal and an adenosine deaminase domain. The fusion protein can be used to achieve A→G base editing.

[0859] In a specific embodiment of the present invention, the fusion protein comprises a nuclear localization signal, a cytidine deaminase domain, and an adenosine deaminase domain. In a specific embodiment of the present invention, the fusion protein comprises one, two, or three nuclear localization signals and a deaminase domain. In a specific embodiment of the present invention, the fusion protein comprises a UGI domain. In a specific embodiment of the present invention, the fusion protein comprises one, two, or three nuclear localization signals, a deaminase domain, and one or two UGI domains.

[0860] In a specific embodiment of the present invention, the fusion protein can be used to achieve transcriptional activation of a specific target gene, for example, in combination with a guide polynucleotide to achieve transcriptional activation of a specific target gene. In a specific embodiment of the present invention, the fusion protein comprises a nuclear localization signal and a transcriptional activation domain.

[0861] In a specific embodiment of the present invention, the fusion protein can be used to achieve transcriptional inhibition of a specific target gene, for example, in combination with a guide polynucleotide to achieve transcriptional inhibition of a specific target gene. In a specific embodiment of the present invention, the fusion protein comprises a nuclear localization signal and a transcriptional inhibition domain.

[0862] In a specific embodiment of the present invention, the fusion protein can be used to achieve methylation of a specific target sequence, for example, in combination with a guide polynucleotide to achieve methylation of a specific target sequence. In a specific embodiment of the present invention, the fusion protein comprises a nuclear localization signal and a DNA methylation domain.

[0863] In a specific embodiment of the present invention, the fusion protein can be used to achieve demethylation of a specific target sequence, for example, in combination with a guide polynucleotide to achieve demethylation of a specific target sequence. In a specific embodiment of the present invention, the fusion protein comprises a nuclear localization signal and a DNA demethylation domain.

[0864] In a preferred embodiment of the present invention, the nuclease domain comprises a polypeptide having ssDNA cleavage activity and / or a polypeptide having dsDNA cleavage activity.

[0865] In a preferred embodiment of the present invention, the nuclease domain comprises a polypeptide having ssDNA cleavage activity.

[0866] In a preferred embodiment of the present invention, the nuclease domain comprises a polypeptide having dsDNA cleavage activity.

[0867] In a specific embodiment of the present invention, the Cas protein or inactivated variant is directly or indirectly linked to the homologous or heterologous functional domain.

[0868] In a preferred embodiment of the present invention, the direct connection is covalent connection, and the indirect connection is connection via an amino acid linker or a non-amino acid linker.

[0869] In a more preferred embodiment of the present invention, the homologous or heterologous functional domain is fused or conjugated at the N-terminus, C-terminus or internally relative to the Cas protein or inactivated variant.

[0870] In the present invention, the fusion protein refers to the connection between the element (1) and the element (2) via a peptide segment, or a direct connection; the conjugate refers to the connection between the element (1) and the element (2) via a non-peptide chemical bond.

[0871] In a specific embodiment of the present invention, the PAM sequence recognizable by the fusion protein or conjugate is the same as the PAM sequence recognizable by the Cas protein.

[0872] On the other hand, a technical solution provided by the present invention is: an isolated nucleic acid, which encodes the Cas protein as described in the present invention, the inactivated variant of the Cas protein as described in the present invention, or the fusion protein or conjugate as described in the present invention.

[0873] In some embodiments of the invention, the nucleic acid encodes a Cas protein as described herein or a fusion protein as described herein.

[0874] In a preferred embodiment of the invention, the nucleic acid is codon-optimized for expression in a cell.

[0875] In a more preferred embodiment of the invention, the nucleic acid is codon-optimized for expression in a eukaryote, a mammal such as a human or non-human mammal, a plant, an insect, a bird, a reptile, a rodent (e.g., mouse, rat), a fish, a worm / nematode, or a yeast.

[0876] On the other hand, the present invention provides a technical solution: a CRISPR-Cas protein system, the CRISPR-Cas protein system comprising:

[0877] a. The Cas protein according to the present invention, the inactivated variant of the Cas protein according to the present invention, the fusion protein or conjugate according to the present invention, or the nucleic acid according to the present invention; and

[0878] b. a guide polynucleotide, or a polynucleotide sequence encoding the guide polynucleotide;

[0879] The Cas protein, the inactivated variant of the Cas protein, or the fusion protein or conjugate forms a complex with the guide polynucleotide; the guide polynucleotide comprises a guide sequence, and the guide sequence is engineered to guide the sequence-specific binding of the complex to the target nucleic acid.

[0880] In specific embodiments of the invention, the guide polynucleotide comprises a direct repeat sequence linked to a guide sequence.

[0881] In a specific embodiment of the invention, the direct repeat sequence is at least 50% identical to any one of SEQ ID NOs: 462-922.

[0882] In certain embodiments of the invention, the guide polynucleotide comprises a direct repeat sequence linked to a guide sequence. Further, in some embodiments, the direct repeat sequence is at least 50% identical to any one of SEQ ID NOs: 462-922. In some embodiments, the direct repeat sequence is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to any one of SEQ ID NOs: 462-922. Further, in some specific embodiments, the direct repeat sequence comprises or is a sequence shown in any one of SEQ ID NOs: 462-922.

[0883] In a specific embodiment of the invention, the guide sequence comprises 15-60 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-50 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-40 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-35 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-30 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-25 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 18-25 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 20-25 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 18-22 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 20-22 nucleotides. In specific embodiments of the invention, the guide sequence comprises 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.

[0884] In a specific embodiment of the invention, the guide sequence hybridizes to the target nucleic acid, and the guide sequence is 90%-100% complementary to the target nucleic acid.

[0885] In specific embodiments of the invention, the guide sequence hybridizes to the target nucleic acid.

[0886] In specific embodiments of the invention, the guide sequence hybridizes to the target nucleic acid, with no more than one nucleotide mismatch between the guide sequence and the target nucleic acid.

[0887] In a specific embodiment of the invention, the direct repeat sequence comprises 15-100 nucleotides. In a specific embodiment of the invention, the direct repeat sequence comprises 15-90 nucleotides. In a specific embodiment of the invention, the direct repeat sequence comprises 15-80 nucleotides. In a specific embodiment of the invention, the direct repeat sequence comprises 15-70 nucleotides. In a specific embodiment of the invention, the direct repeat sequence comprises 15-60 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-50 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 15-40 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 20-40 nucleotides. In a specific embodiment of the invention, the guide sequence comprises 20-30 nucleotides. In specific embodiments of the invention, the guide sequence comprises 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 nucleotides.

[0888] In a specific embodiment of the invention, the guide sequence is located at the 3' end of the direct repeat sequence.

[0889] In a specific embodiment of the invention, the guide sequence is located at the 5' end of the direct repeat sequence.

[0890] In a specific embodiment of the invention, the guide polynucleotide further comprises a tracrRNA.

[0891] In some embodiments of the invention, the tracrRNA sequence is at least 50% identical to any one of SEQ ID NOs: 923-1183. In some embodiments of the invention, the tracrRNA sequence is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to any one of SEQ ID NOs: 923-1183.

[0892] In a specific embodiment of the present invention, the tracrRNA can be complementary to the direct repeat sequence. In general, the complementary pairing is a complementary pairing of partial bases. In a specific embodiment of the present invention, the tracrRNA can interact with the direct repeat sequence.

[0893] In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence through a nucleotide sequence. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence through a nucleotide sequence consisting of 1-10 nucleotides. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence through a nucleotide sequence consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence through a nucleotide sequence consisting of 4 nucleotides. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence through a 5'-GAAA-3' sequence.

[0894] In a specific embodiment of the present invention, the tracrRNA sequence is located at the 3' end of the direct repeat sequence.

[0895] In a specific embodiment of the present invention, the tracrRNA sequence is located at the 5' end of the direct repeat sequence.

[0896] In a specific embodiment of the invention, the tracrRNA comprises 10-200 nucleotides. In a specific embodiment of the invention, the tracrRNA comprises 10-190, 10-180, 10-170, 10-160, 10-150, 10-140, 10-130, 10-120, 10-110, 10-100, 10-90, 10-80, 10-70, 10-60, 10-50, 10- or 40, 10-30, 10-20, 10-100, 10-100, 10-100, 10-100, 10-100, 10-100, 20-100, 30-100, 40-100, 20-90, 20-80, 20-70, 20-60, 20-50, or 30-50 nucleotides. In a specific embodiment of the present invention, the tracrRNA comprises 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 94, 95, 96, 97, 98, 99, or 100 nucleotides.

[0897] In a preferred embodiment of the present invention, the guiding polynucleotide is the guiding polynucleotide described in the present invention.

[0898] In a specific embodiment of the present invention, the target nucleic acid is DNA or RNA, preferably dsDNA or ssDNA.

[0899] In a preferred embodiment of the present invention, the DNA is eukaryotic DNA; preferably, the eukaryotic DNA is non-human mammalian DNA, non-human primate DNA, human DNA, plant DNA, insect DNA, bird DNA, reptile DNA, rodent DNA, fish DNA, worm / nematode DNA or yeast DNA.

[0900] In a specific embodiment of the present invention, the target nucleic acid is a disease or disorder-associated gene or a signal transduction biochemical pathway-associated gene, or the target nucleic acid is a reporter gene; for example, the disease or disorder is a blood system disease or disorder, an ophthalmic disease or disorder, a nervous system disease or disorder, a respiratory system disease or disorder, a liver disease or disorder, a metabolic system disease or disorder, cancer or an infectious disease.

[0901] On the other hand, a technical solution provided by the present invention is: a vector system, wherein the vector system comprises one or more recombinant vectors, and the recombinant vectors comprise the isolated nucleic acid as described in the present invention, or the CRISPR-Cas protein system as described in the present invention.

[0902] In a specific embodiment of the present invention, the recombinant vector further comprises a regulatory sequence.

[0903] In a specific embodiment of the present invention, the vector system comprises one or more recombinant vectors, which comprise a polynucleotide sequence encoding the Cas protein, Cas protein inactivated variant or fusion protein or conjugate of the present invention, and a polynucleotide sequence encoding the guide polynucleotide.

[0904] In a specific embodiment of the present invention, the polynucleotide sequence encoding the Cas protein, Cas protein inactivated variant or fusion protein or conjugate is operably linked to the regulatory sequence 1.

[0905] In a specific embodiment of the present invention, the polynucleotide sequence encoding the guide polynucleotide is operably linked to regulatory sequence 2.

[0906] Furthermore, in a specific embodiment of the present invention, the regulatory sequence 1 and the regulatory sequence 2 are identical or different sequences.

[0907] In a preferred embodiment of the present invention, the regulatory sequence is optionally selected from: one or more of a promoter, an enhancer, an internal ribosome entry site and a transcription termination signal; the promoter is, for example, a constitutive promoter, an inducible promoter, a broad-spectrum promoter or a tissue-specific promoter, and / or the transcription termination signal is, for example, a polyadenylation signal or a poly-U sequence.

[0908] In a specific embodiment of the present invention, the backbone of the recombinant vector is an adeno-associated virus vector, a lentivirus vector, a ribonucleoprotein complex or a virus-like particle.

[0909] In a preferred embodiment of the present invention:

[0910] When the backbone is an adeno-associated viral vector, the adeno-associated viral vector is a recombinant adeno-associated viral vector of serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12 or AAV13;

[0911] When the backbone is a lentiviral vector, the lentiviral vector is pseudotyped with an envelope protein; preferably, the isolated nucleic acid is linked to an aptamer sequence;

[0912] When the backbone is a virus-like particle, the isolated nucleic acid is linked to a gene encoding a gag protein.

[0913] On the other hand, a technical solution provided by the present invention is: a delivery system, which comprises: (1) a delivery tool, and (2) the Cas protein as described in the present invention, the guiding polynucleotide as described in the present invention, the inactivated variant of the Cas protein as described in the present invention, the fusion protein or conjugate as described in the present invention, the nucleic acid as described in the present invention, the CRISPR-Cas protein system as described in the present invention, or the vector system as described in the present invention.

[0914] In a preferred embodiment of the present invention, the delivery vehicle is a virus, lipid nanoparticle, nanoparticle, liposome, exosome, microbubble or gene gun.

[0915] In a more preferred embodiment of the present invention, the delivery vehicle is a lipid nanoparticle, which comprises the guide polynucleotide and mRNA encoding the Cas protein, the inactivated variant of the Cas protein, or the fusion protein or conjugate.

[0916] On the other hand, a technical solution provided by the present invention is: a cell, comprising the Cas protein as described in the present invention, the guide polynucleotide as described in the present invention, the inactivated variant of the Cas protein as described in the present invention, the fusion protein or conjugate as described in the present invention, the nucleic acid as described in the present invention, the CRISPR-Cas protein system as described in the present invention, or the vector system as described in the present invention.

[0917] In some embodiments of the invention, the cell is a prokaryotic cell.

[0918] In some embodiments of the invention, the cell is a eukaryotic cell.

[0919] In some embodiments of the invention, the eukaryotic cell is a mammalian cell.

[0920] On the other hand, a technical solution provided by the present invention is: a pharmaceutical composition, comprising the Cas protein as described in the present invention, the guide polynucleotide as described in the present invention, the inactivated variant of the Cas protein as described in the present invention, the fusion protein or conjugate as described in the present invention, the nucleic acid as described in the present invention, the CRISPR-Cas protein system as described in the present invention, the vector system as described in the present invention, the delivery system as described in the present invention or the cell as described in the present invention.

[0921] Preferably, the pharmaceutical composition comprises pharmaceutically acceptable excipients.

[0922] On the other hand, a technical solution provided by the present invention is: a kit comprising the Cas protein as described in the present invention, the guide polynucleotide as described in the present invention, the inactivated variant of the Cas protein as described in the present invention, the fusion protein or conjugate as described in the present invention, the nucleic acid as described in the present invention, the CRISPR-Cas protein system as described in the present invention, the vector system as described in the present invention, the delivery system as described in the present invention or the cell as described in the present invention.

[0923] In a preferred embodiment of the present invention, the kit further comprises a cutting buffer. The cutting buffer can be any buffer known in the art that is suitable for Cas protein cutting target nucleic acid.

[0924] On the other hand, a technical solution provided by the present invention is: use of the Cas protein as described in the present invention, the guide polynucleotide as described in the present invention, the inactivated variant of the Cas protein as described in the present invention, the fusion protein or conjugate as described in the present invention, the nucleic acid as described in the present invention, the CRISPR-Cas protein system as described in the present invention, the vector system as described in the present invention, the delivery system as described in the present invention, the cell as described in the present invention, the pharmaceutical composition as described in the present invention, or the kit as described in the present invention in the preparation of a reagent or drug for diagnosing, treating and / or preventing a disease or condition associated with a target nucleic acid.

[0925] In specific embodiments of the invention, the disease or condition is a blood disease or condition, an ophthalmic disease or condition, a nervous system disease or condition, a respiratory system disease or condition, a liver disease or condition, a metabolic system disease or condition, cancer or an infectious disease; and / or the agent or drug is used to: cut one or more target nucleic acid molecules or cause a nick in one or more target nucleic acid molecules, activate or upregulate the expression of one or more target nucleic acid molecules, activate or inhibit the transcription of one or more target nucleic acid molecules, inactivate one or more target nucleic acid molecules, visualize, label or detect one or more target nucleic acid molecules, bind one or more target nucleic acid molecules, transport one or more target nucleic acid molecules, and mask one or more target nucleic acid molecules.

[0926] On the other hand, a technical solution provided by the present invention is: a method for detecting, binding or cutting a target nucleic acid, the method comprising contacting the target nucleic acid with the Cas protein as described in the present invention, the guide polynucleotide as described in the present invention, the inactivated variant of the Cas protein as described in the present invention, the fusion protein or conjugate as described in the present invention, the nucleic acid as described in the present invention, the CRISPR-Cas protein system as described in the present invention, the vector system as described in the present invention, the delivery system as described in the present invention, the cell as described in the present invention, the pharmaceutical composition as described in the present invention or the kit as described in the present invention.

[0927] In a preferred embodiment of the present invention, the method is a method for non-diagnostic and / or therapeutic purposes; and / or the fusion protein or conjugate comprises a detectable label, such as a label detectable by fluorescence, Southern blotting or FISH.

[0928] In a more preferred embodiment of the present invention, when the method is for cutting a target nucleic acid, the method further comprises using a cutting buffer to carry out a cutting reaction. The cutting buffer can be any buffer known in the art that is suitable for Cas protein cutting a target nucleic acid.

[0929] On the other hand, a technical solution provided by the present invention is: a method for changing the state of a cell, the method comprising using the Cas protein as described in the present invention, the guide polynucleotide as described in the present invention, the inactivated variant of the Cas protein as described in the present invention, the fusion protein or conjugate as described in the present invention, the nucleic acid as described in the present invention, the CRISPR-Cas protein system as described in the present invention, the vector system as described in the present invention, the delivery system as described in the present invention, the cell as described in the present invention, the pharmaceutical composition as described in the present invention or the kit as described in the present invention to contact the cell, thereby changing the cell state.

[0930] In some embodiments of the invention, the method results in one or more of: increased or decreased expression of a specific gene, induction of cellular senescence in vitro or in vivo, cell cycle arrest in vitro or in vivo, cell growth promotion and / or cell growth inhibition in vitro or in vivo, induction of anergy in vitro or in vivo, induction of apoptosis in vitro or in vivo, and induction of necrosis in vitro or in vivo.

[0931] In a more preferred embodiment of the present invention, the method is a method for non-diagnostic and / or therapeutic purposes.

[0932] On the other hand, a technical solution provided by the present invention is: a method for diagnosing, treating or preventing a disease or condition associated with a target nucleic acid, administering a Cas protein as described in the present invention, a guide polynucleotide as described in the present invention, an inactivated variant of a Cas protein as described in the present invention, a fusion protein or conjugate as described in the present invention, a nucleic acid as described in the present invention, a CRISPR-Cas protein system as described in the present invention, a vector system as described in the present invention, a delivery system as described in the present invention, a cell as described in the present invention, a pharmaceutical composition as described in the present invention, or a kit as described in the present invention to a sample of a subject in need or to a subject in need.

[0933] In a specific embodiment of the present invention, the disease or disorder is a hematological disease or disorder, an ophthalmic disease or disorder, a nervous system disease or disorder, a respiratory system disease or disorder, a liver disease or disorder, a metabolic system disease or disorder, cancer or an infectious disease.

[0934] On the other hand, a technical solution provided by the present invention is: the Cas protein as described in the present invention, the guide polynucleotide as described in the present invention, the inactivated variant of the Cas protein as described in the present invention, the fusion protein or conjugate as described in the present invention, the nucleic acid as described in the present invention, the CRISPR-Cas protein system as described in the present invention, the vector system as described in the present invention, the delivery system as described in the present invention, the cell as described in the present invention, the pharmaceutical composition as described in the present invention or the kit as described in the present invention, which is used to diagnose, treat or prevent diseases or disorders associated with target nucleic acids.

[0935] In a specific embodiment of the present invention, the disease or disorder is a hematological disease or disorder, an ophthalmic disease or disorder, a nervous system disease or disorder, a respiratory system disease or disorder, a liver disease or disorder, a metabolic system disease or disorder, cancer or an infectious disease.

[0936] On the basis of conforming to the common sense in this field, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0937] The reagents and raw materials used in the present invention are commercially available. BRIEF DESCRIPTION OF THE DRAWINGS

[0938] none. DETAILED DESCRIPTION

[0939] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, procedures in molecular genetics, nucleic acid chemistry, chemistry, molecular biology, biochemistry, cell culture, microbiology, cell biology, genomics, and recombinant DNA used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.

[0940] In the present invention, "a plurality of" refers to greater than or equal to two.

[0941] In the present invention, the letters in the amino acid sequence represent the single-letter abbreviations of amino acids known in the art, such as those described in J.Biol.Chem, 243, p3558 (1968): alanine: Ala-A, arginine: Arg-R, aspartic acid: Asp-D, cysteine: Cys-C, glutamine: Gln-Q, glutamic acid: Glu-E, histidine: His-H, glycine: Gly-G, asparagine: Asn-N, tyrosine: Tyr-Y, proline: Pro-P, serine: Ser-S, methionine: Met-M, lysine: Lys-K, valine: Val-V, isoleucine: Ile-I, phenylalanine: Phe-F, leucine: Leu-L, tryptophan: Trp-W, threonine: Thr-T.

[0942] In the present invention, "amino acid difference" refers to the difference in amino acid residues at specific sites in the amino acid sequence of a protein, including substitution, addition or reduction.

[0943] It is well known to those skilled in the art that in a protein or peptide, two adjacent amino acids each remove an OH or H, dehydrate and condense to form a peptide bond, and each amino acid actually exists in the form of an amino acid residue. Therefore, in this disclosure, the terms "amino acid" and "amino acid residue" generally represent the same meaning. In addition, in order to simplify the expression, the amino acid residue before substitution is retained before the site where the amino acid residue is located in this disclosure, the letter before the site represents the original amino acid residue, and the letter after the site represents the amino acid residue after substitution. For example, S211 represents that the original amino acid residue at site 211 is S. When it is replaced by R, it can be expressed as S211R.

[0944] In the present invention, when an amino acid is substituted, it means that it is replaced by another amino acid residue that is different from the original amino acid residue. If the original amino acid residue is a positively charged amino acid and it is replaced by a positively charged amino acid, it means that it is replaced by another positively charged amino acid residue that is different from the original amino acid residue. For example, if the original amino acid residue is R and it is replaced by a positively charged amino acid, it means that it is replaced by H or K.

[0945] Sequence identity

[0946] As used herein, the term "identity" or "percent identity" refers to the matching of sequences between two polypeptides or between two nucleic acids. When a certain position in the two sequences being compared is occupied by the same base or amino acid monomer subunit (e.g., a certain position in each of the two DNA molecules is occupied by adenine, or a certain position in each of the two polypeptides is occupied by lysine), then the molecules are identical at that position. The "percent sequence identity" between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions being compared × 100%. For example, if 6 out of 10 positions in two sequences match, then the two sequences have 60% sequence identity. Typically, comparisons are made when two sequences are aligned to produce maximum sequence identity. Such comparisons can be performed using published and commercially available alignment algorithms and programs, such as, but not limited to, ClustalΩ, MAFFT, Probcons, T-Coffee, Probalign, BLAST, which can be reasonably selected by one of ordinary skill in the art. Those skilled in the art can determine appropriate parameters for aligning sequences, including, for example, any algorithms needed to achieve better alignment or optimal comparison over the entire length of the sequences being compared, as well as any algorithms needed to achieve better alignment or optimal comparison over a portion of the sequences being compared.

[0947] CRISPR-Cas protein system

[0948] As used herein, the terms "Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR-Associated (Cas) (CRISPR-Cas) System" or "CRISPR System" are used interchangeably and have the meaning generally understood by those skilled in the art, which generally include transcripts or other elements related to the expression of CRISPR-associated ("Cas") genes, or transcripts or other elements capable of directing the activity of the Cas genes. Such transcripts or other elements may include sequences encoding Cas effector proteins and guide polynucleotides.

[0949] In 2015, Zhang Feng's group discovered Cas protein a, which is classified as type V in the Class II CRISPR-Cas system. Following detailed studies of subtype VA (Cas protein a), Zhang Feng's group also reported Cas protein b (C2C1) in 2015. In 2017, Burstein et al. reported the Cas protein e (CasX) nuclease. In 2019, Winston X. Yan et al. detailed the newly discovered type V Cas effector proteins, Cas protein c, Cas protein h, Cas protein i, and Cas protein g, through bioinformatics analysis.

[0950] In some embodiments, the Cas protein described herein refers to an amino acid sequence comprising or being a protein having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% sequence identity compared to any one of SEQ ID NOs: 1-461. When the CRISPR-Cas protein system includes a fusion protein or conjugate comprising the Cas protein and a protein domain, the percentage of sequence identity between the Cas protein portion of the fusion protein or conjugate and the reference sequence is calculated.

[0951] In the present invention, the CRISPR-Cas protein system comprises a Cas protein having at least 50% sequence identity with any one of SEQ ID NOs: 1-461, or a nucleic acid encoding the Cas protein; and a guide polynucleotide or a nucleic acid encoding the guide polynucleotide; the guide polynucleotide comprises a direct repeat sequence connected to a guide sequence, the guide sequence is engineered to hybridize with a target nucleic acid, and the guide polynucleotide is capable of forming a complex with the Cas protein and guiding the complex to sequence-specific binding to the target nucleic acid.

[0952] Guide polynucleotide

[0953] As used herein, the terms "guide polynucleotide" and "guide RNA" are used interchangeably to refer to molecules that form a complex with the Cas protein in the CRISPR-Cas system and guide the complex to the target sequence. Typically, the guide polynucleotide comprises a backbone sequence connected to the guide sequence, and the guide sequence can hybridize with the target sequence. The backbone sequence typically comprises a direct repeat sequence and sometimes may further comprise a tracrRNA sequence. In some embodiments, the guide polynucleotide does not comprise a tracrRNA sequence. In some embodiments, the guide polynucleotide comprises a tracrRNA sequence.

[0954] In some embodiments, the guide polynucleotide of the CRISPR-Cas protein system is a guide RNA. In some embodiments, the guide polynucleotide is a chemically modified guide polynucleotide. In some embodiments, the guide polynucleotide comprises at least one chemically modified nucleotide.

[0955] In some embodiments, the guide polynucleotide comprises at least one guide sequence (also known as a spacer sequence) linked to at least one direct repeat (DR). In some embodiments, the guide sequence is located at the 3' end of the direct repeat. In some embodiments, the guide sequence is located at the 5' end of the direct repeat.

[0956] In some embodiments, the tracrRNA sequence is linked to the direct repeat sequence.

[0957] In some embodiments, the tracrRNA sequence is located at the 5' or 3' end of the direct repeat sequence. In some embodiments, the tracrRNA sequence is located at the 5' end of the direct repeat sequence. In some embodiments, the tracrRNA sequence is located at the 3' end of the direct repeat sequence.

[0958] In some embodiments, the nucleotide sequence of the guide polynucleotide comprises, from 5' to 3', tracrRNA, a direct repeat sequence, and a guide sequence.

[0959] In some embodiments, the nucleotide sequence of the guide polynucleotide comprises, from 5' to 3', tracrRNA, a linker sequence, a direct repeat sequence, and a guide sequence.

[0960] In some embodiments, the nucleotide sequence of the guide polynucleotide comprises, from 5' to 3', tracrRNA, a loop sequence, a direct repeat sequence, and a guide sequence.

[0961] In some embodiments, the structure of the guide polynucleotide is 5'-tracrRNA-loop-direct repeat sequence-guide sequence-3'.

[0962] In some embodiments, the tracrRNA and direct repeat sequence of the guide polynucleotide are linked by a nucleotide sequence.

[0963] In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence by a nucleotide sequence consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence by a nucleotide sequence consisting of 4 nucleotides. In a specific embodiment of the present invention, the tracrRNA sequence is connected to the direct repeat sequence by a 5'-GAAA-3' sequence.

[0964] In some embodiments, the guide sequence has sufficient complementarity to the target nucleic acid sequence to hybridize to the target nucleic acid and guide sequence-specific binding of the CRISPR-Cas protein complex to the target nucleic acid. In some embodiments, the guide sequence has 100% complementarity to the target nucleic acid, but the guide sequence can have less than 100% complementarity to the target nucleic acid, such as at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% complementarity.

[0965] In some embodiments, the guide sequence is engineered to hybridize to the target nucleic acid with no more than two nucleotide mismatches. In some embodiments, the guide sequence is engineered to hybridize to the target nucleic acid with no more than one nucleotide mismatches. In some embodiments, the guide sequence is engineered to hybridize to the target nucleic acid with or without mismatches.

[0966] In some embodiments, the CRISPR-Cas protein system comprises at least 2, at least 3, at least 4, at least 5, at least 10, or at least 20 different guide polynucleotides. In some embodiments, the guide polynucleotides target at least 2, at least 3, at least 4, at least 5, at least 10, or at least 20 different target nucleic acid molecules, or target at least 2, at least 3, at least 4, at least 5, at least 10, or at least 20 different regions of one or more target nucleic acid molecules.

[0967] In some embodiments, the guide polynucleotide includes a constant direct repeat sequence located upstream of a variable guide sequence. In some embodiments, a plurality of guide polynucleotides are part of an array (which can be part of a vector, such as a viral vector or plasmid). For example, a guide array comprising the sequence DR-spacer-DR-spacer-DR-spacer-...-DR-spacer can include a plurality of unique unprocessed guide polynucleotides (one for each DR-spacer or spacer-DR sequence). Once introduced into a cell or cell-free system, the array is processed by the Cas protein into several separate mature guide polynucleotides. This allows multiplexing, such as delivering multiple guide polynucleotides to a cell or system to target multiple target nucleic acids or multiple regions within a single target nucleic acid.

[0968] The ability of a guide polynucleotide to guide a complex (CRISPR complex) to bind sequence-specifically to a target nucleic acid can be assessed by any suitable assay. For example, components of a CRISPR system sufficient to form a complex (CRISPR complex), including the guide polynucleotide to be tested, can be provided to a host cell with the corresponding target nucleic acid molecule, such as by transfection of a vector encoding the components of the CRISPR complex, and preferential cleavage within the target sequence can be assessed. Similarly, cleavage of a target nucleic acid sequence can be assessed in a test tube by providing a target nucleic acid, components of a CRISPR complex, including the guide polynucleotide to be tested and a control guide polynucleotide that is different from the test guide polynucleotide, and comparing the ability to bind to the target nucleic acid or the rate at which the target nucleic acid is cleaved between the test and control guide polynucleotides. The ability of a CRISPR complex to cleave a target nucleic acid or target nucleic acid can also be assessed by the assays described above.

[0969] Cas protein mutants

[0970] In some embodiments, the Cas protein provided herein comprises one or more mutations, such as a single amino acid insertion, a single amino acid deletion, a single amino acid substitution, or a combination thereof, compared to a wild-type Cas protein (SEQ ID NO: 1-461). In some examples, the Cas protein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 9, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82 128, 129, or 130 amino acid changes (e.g., insertions, deletions, or substitutions) in the guide polynucleotide, but retain the ability to bind to a target nucleic acid molecule that is complementary to the guide sequence of the guide polynucleotide and / or retain the ability to process an RNA transcript comprising the guide sequence into a guide polynucleotide molecule.In some examples, the Cas protein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 , 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129 or 130 amino acid changes (e.g., insertions, deletions or substitutions) but retains the ability to bind to a target nucleic acid molecule that is complementary to the guide sequence of the guide polynucleotide.

[0971] One type of modification or mutation includes replacing amino acid residues with amino acid residues having similar biochemical properties, i.e., conservative substitutions. Typically, conservative substitutions have little or no effect on the activity of the resulting protein or peptide. For example, conservative substitutions are amino acid substitutions in the Cas protein that do not substantially affect the binding of the Cas protein to the target nucleic acid molecule complementary to the guide sequence of the gRNA molecule, and / or the process of processing the guide array RNA transcript into the gRNA molecule.

[0972] More substantial changes can be made by using less conservative substitutions, for example, by selecting residues that differ more in maintaining: (a) the structure of the polypeptide backbone in the region where the substitution occurs, for example, as a helical or sheet conformation; (b) the charge or hydrophobicity of the region that interacts with the target site; or (c) the bulk of the side chain. Substitutions that would generally be expected to produce the greatest changes in polypeptide function are (a) substitutions between a hydrophilic residue (e.g., serine or threonine) and a hydrophobic residue (e.g., leucine, isoleucine, phenylalanine, valine, or alanine); (b) substitutions between cysteine ​​or proline and any other residue; (c) substitutions between a residue with a positively charged side chain (e.g., lysine, arginine, or histidine) and a negatively charged residue (e.g., glutamic acid or aspartic acid); or (d) substitutions between a residue with a bulky side chain (e.g., phenylalanine) and a residue without a side chain (e.g., glycine).

[0973] Cas protein active fragment

[0974] In the present invention, the Cas protein may only include a WED-I domain, a Helical-I1 domain, a PI domain, a Helical-I2 domain, a Helical-II domain, a WED-II domain, a Ruvc-I domain, a Helical-III domain, a BH domain, a Ruvc-II domain, a Nuc domain and / or a Ruvc-III domain.

[0975] The Cas protein of the present invention, in addition to comprising the said domain, may also comprise the domains of other Cas proteins in the prior art, which together form the complete structure of the Cas protein to achieve the function of the Cas protein of the present invention, including but not limited to retaining the ability of the Cas protein to bind to the target nucleic acid molecule complementary to the guide sequence of the guide polynucleotide, and / or retaining the ability to process the RNA transcript comprising the guide sequence into a guide polynucleotide molecule.

[0976] Cas protein inactive variants

[0977] By making the RuvC domain of the Cas protein inactive through point mutation, the Cas protein will lose its endonuclease activity. The resulting dCas protein (dead Cas protein) can only bind to the target gene under the mediation of the guide polynucleotide, but does not have the function of cutting DNA.

[0978] The RuvC domain of the Cas protein can also be partially inactivated by point mutation to form a Cas protein nickase (nCas protein), which binds to the target gene under the guidance of the guide polynucleotide and cuts one of the single strands in the double-stranded nucleic acid without cutting the other single strand.

[0979] Therefore, the dCas protein or nCas protein can be fused or conjugated with other domains (including but not limited to deaminase domains, transcription activation domains, transcription repression domains, methylation domains, demethylation domains, histone acetylation domains, and histone deacetylation domains), guided to the target sequence of the target nucleic acid by the guide polynucleotide, and then the corresponding functions are performed with the help of the other domains; for example, the conversion of base C→T is achieved by deaminating the cytosine base, the conversion of base A→G is achieved by deaminating the adenine base, transcription repression is achieved by the transcription repression domain KRAB, and transcription is promoted by the transcription activation domain VP64.

[0980] Protein domain

[0981] In some embodiments, the Cas protein or inactive variant of the Cas protein is covalently linked or fused to a homologous or heterologous protein domain.

[0982] In some embodiments, the protein domain is optionally selected from one or more of the following: a subcellular localization signal, a DNA binding domain, a protease domain, a transcription activation domain, a transcription repression domain, a nuclease domain, a deaminase domain, a uracil DNA glycosylase domain (UDG), a uracil DNA glycosylase inhibitory domain (UGI), a methylase, a demethylase, a transcription release factor, a histone acetylase domain, a histone deacetylase domain, a DNA ligase, an epitope tag, and a reporter domain.

[0983] In some embodiments of the invention, the deaminase domain is selected from the group consisting of: APOBEC1, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, activation-induced cytidine deaminase (AID), CDA from lamprey, and a mutant of adenosine deaminase engineered to act on DNA (TadA).

[0984] In some embodiments, the transcriptional activation domain is selected from the group consisting of: P65, VPR, VP16, VP64, VTR1, VTR2, VTR3, p65, MyoD1, HSF1, RTA, SET7 / 9, and histone acetyltransferase. In some embodiments, the transcriptional activation domain is optionally selected from: sequence ETFSDLWKL from p53TAD1, sequence DDIEQWFTE from p53TAD2, sequence SDIMDFVLK from MLL, sequence DLLDFSMMF from E2A, sequence ETLDFSLVT from Rtg3, sequence RKILNDLSS from CREB, sequence EAILAELKK from CREBaB6, sequence DDVVQYLNS from Gli3, sequence DDVYNYLFD from Gal4, sequence DLFDYDFLV from Oaf1, sequence DFFDYDLLF from Pip2, sequence EDLYSILWS from Pdr1, sequence TDLYHTLWN from Pdr3.

[0985] In some embodiments, the transcriptional repression domain is selected from the group consisting of KOX1, KAP-1, MAD, FKHR, EGR-1, ERD, SID, a tandem of SID (e.g., SID4X), TIEG, v-ERB-A, MBD2, MBD3, TRa, a histone methyltransferase, a histone deacetylase (HDAC), a nuclear hormone receptor (e.g., an estrogen receptor or a thyroid hormone receptor), a DNMT family member (e.g., DNMT1, DNMT3A, DNMT3B), the KRAB domain of MeCP2, ROM2, and AtHD2A.

[0986] In some embodiments, the transcriptional repression domain is a KRAB domain from the KOX1 protein.

[0987] In some embodiments, the nuclease domain is selected from FokI, a polypeptide having ssDNA cleavage activity, and a polypeptide having dsDNA cleavage activity.

[0988] In some embodiments, the methylase domain is selected from DNA methylases, including but not limited to DNMT1, DNMT3a, and DNMT3b.

[0989] In some embodiments, the demethylase is selected from TET1CD, TET1, ROS1, DME, DML2, and DML3.

[0990] Methylation and demethylation are recognized in the art as important means of epigenetic gene regulation.

[0991] In some embodiments, the homologous or heterologous protein domain is a sequence tag useful for dissolving, purifying or detecting the fusion protein or conjugate. Suitable protein tag sequences are provided herein, and these sequences include but are not limited to biotin carboxylase carrier protein (BCCP) label, myc label, calmodulin label, FLAG label, hemagglutinin (HA) label, polyhistidine tag (also referred to as His label), maltose binding protein (MBP) label, nus label, glutathione-S-transferase (GST) label, green fluorescent protein (GFP) label, thioredoxin label, S-label, Softag (for example, Softag 1, Softag 3), strep-label, biotin ligase label, F1AsH label, V5 label and SBP label. Other suitable sequences will be apparent to those of ordinary skill in the art.

[0992] Subcellular localization signals

[0993] In some embodiments, the Cas protein is fused to at least one homologous or heterologous subcellular localization signal. In some embodiments, the Cas protein is fused to at least one homologous or heterologous subcellular localization signal. Exemplary subcellular localization signals include organelle localization signals, such as nuclear localization signals (NLS), nuclear export signals (NES), or mitochondrial localization signals.

[0994] Non-limiting examples of NLSs include NLS sequences derived from: the NLS of the SV40 virus large T antigen, which has the amino acid sequence PKKKRKV; the NLS from nucleoplasmin (e.g., sequence KRPAATKKAGQAKKKK); c-myc NLS having the amino acid sequence PAAKRVKLD or RQRRNELKRSP; hRNPA1M9NLS having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY; the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV from the IBB domain; the sequence VSRKRPRP and PPKKARED of myoma T protein; the sequence PQPKKKPL of human p53; the sequence SALIKKKKKMAP of mouse c-ablIV; the sequence DRLRR and PKQKKRK of influenza virus NS1; the sequence RKLKKKIKKL of hepatitis virus delta antigen; the sequence REKKKFLKRR of mouse Mx1 protein; the sequence KRKGDEVDGVDEVAKKKSKK of human PARP enzyme; and the sequence RKCLQAGMNLEARKTKK of steroid hormone receptor. In certain embodiments, the nuclear localization sequence has sufficient intensity to realize driving the fusion protein of the present invention or conjugate to accumulate with detectable amount in the nucleus of eukaryotic cells.In general, the intensity of nuclear localization activity can be derived from the number of NLSs, one or more specific NLSs used or a combination of these factors.The detection of accumulation in the nucleus can be carried out by any suitable technology.For example, a detectable label can be fused to the Cas protein so that the position in the cell can be visualized, such as with the means of detecting the position of the nucleus (for example, a specific dye to the nucleus, such as DAPI) combined. The nucleus can also be separated from the cell, and then its contents can be analyzed by any suitable method for detecting protein, such as immunohistochemistry, Western blotting or enzyme activity assay. The accumulation in the nucleus can also be indirectly determined in the following manner: such as by measuring the effect of nucleic acid targeting complex formation (for example, measuring DNA or RNA cutting or mutation at the target sequence or measuring the gene expression activity changed due to the influence of DNA or RNA targeting complex formation and / or DNA or RNA targeting Cas protein activity), with no exposure to nucleic acid targeting Cas protein or nucleic acid targeting complex or exposure to the control of nucleic acid targeting Cas protein lacking one or more NLS.

[0995] Vector system

[0996] Another aspect of the present disclosure relates to a vector system comprising the CRISPR-Cas protein system described herein, comprising one or more recombinant vectors comprising a polynucleotide sequence encoding the Cas protein and a polynucleotide sequence encoding the guide polynucleotide.

[0997] In some embodiments, the vector system comprises at least one plasmid or viral recombinant vector (e.g., retrovirus, lentivirus, adenovirus, adeno-associated virus, or herpes simplex virus). In some embodiments, the polynucleotide sequence encoding the Cas protein and the polynucleotide sequence encoding the guide polynucleotide are located on the same recombinant vector. In some embodiments, the polynucleotide sequence encoding the Cas protein and the polynucleotide sequence encoding the guide polynucleotide are located on multiple recombinant vectors.

[0998] In some embodiments, the polynucleotide sequence encoding the Cas protein and / or the polynucleotide sequence encoding the guide polynucleotide are operably connected to a regulatory sequence (also known as a regulatory element). The regulatory element includes a promoter, an enhancer, an internal ribosome entry site (IRES) and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Regulatory elements include regulatory elements that constitutively express the nucleotide sequence in many types of host cells, and regulatory elements that only express the nucleotide sequence in certain host cells (e.g., tissue-specific regulatory sequences). Tissue-specific promoters can be directly expressed primarily in desired tissues of interest, such as muscle, neurons, bone, skin, blood, specific organs (e.g., liver, pancreas) or specific cell types (e.g., lymphocytes). Regulatory elements can also guide expression in a time-dependent manner, such as in a cell cycle-dependent or developmental stage-dependent manner, which may or may not be tissue- or cell-type-specific. In some embodiments, the regulatory element is an enhancer element, such as WPRE, the CMV enhancer, the R-U5 segment in the LTR of HTLV-1, the SV40 enhancer, or the intronic sequence between exons 2 and 3 of rabbit β-globin.

[0999] In some embodiments, the recombinant vector comprises a pol III promoter (e.g., U6 and H1 promoters), a pol II promoter (e.g., retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with RSV enhancer), cytomegalovirus (CMV) promoter (optionally with CMV enhancer), SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, phosphoglycerol kinase (PGK) promoter, or EF1α promoter), or a pol III promoter and a pol II promoter.

[1000] In some embodiments, the promoter is a constitutive promoter, which is continuously active and not regulated by external signals or molecules. Suitable constitutive promoters include, but are not limited to, CMV, RSV, SV40, EF1α, CAG, and β-actin promoters. In some embodiments, the promoter is an inducible promoter regulated by external signals or molecules (e.g., transcription factors).

[1001] In some embodiments, the promoter is a tissue-specific promoter, which can be used to drive the tissue-specific expression of Cas proteins. Suitable muscle-specific promoters include but are not limited to CK8, MHCK7, myoglobin promoter (Mb), desmin (Desmin) promoter, muscle creatine kinase promoter (MCK) and variants thereof, and SPc5-12 synthetic promoters. Suitable immune cell-specific promoters include but are not limited to B29 promoter (B cells), CD14 promoter (monocytes), CD43 promoter (leukocytes and platelets), CD68 (macrophages) and SV40 / CD43 promoter (leukocytes and platelets). Suitable blood cell-specific promoters include but are not limited to CD43 promoter (leukocytes and platelets), CD45 promoter (hematopoietic cells), INF-β (hematopoietic cells), WASP promoter (hematopoietic cells), SV40 / CD43 promoter (leukocytes and platelets), and SV40 / CD45 promoter (hematopoietic cells). Suitable pancreas-specific promoters include but are not limited to elastase-1 promoter. Suitable endothelial cell-specific promoters include, but are not limited to, the Fit-1 promoter and the ICAM-2 promoter. Suitable neuronal tissue / cell-specific promoters include, but are not limited to, the GFAP promoter (astroglial cells), the SYN1 promoter (neurons), and the NSE / RU5' (mature neurons). Suitable kidney-specific promoters include, but are not limited to, the NphsI promoter (podocytes). Suitable bone-specific promoters include, but are not limited to, the OG-2 promoter (osteoblasts, odontoblasts). Suitable lung-specific promoters include, but are not limited to, the SP-B promoter (lung). Suitable liver-specific promoters include, but are not limited to, the SV40 / Alb promoter. Suitable heart-specific promoters include, but are not limited to, α-MHC.

[1002] AAV vectors

[1003] Another aspect of the present disclosure relates to an adeno-associated viral (AAV) vector comprising the CRISPR-Cas protein system described herein, wherein the adeno-associated viral (AAV) vector comprises DNA encoding the Cas protein and guide polynucleotide described herein.

[1004] Delivery of the CRISPR-Cas system via an AAV vector is described in Maeder et al., Nature Medicine 25:229-233 (2019), which has been clinically demonstrated to be safe and effective for subretinal delivery of AAV. Local delivery via subretinal injection, the natural tropism of AAV5 for photoreceptor cells, and the use of the photoreceptor-specific GRK1 promoter are all used to limit the expression of the CRISPR / Cas system to therapeutic target tissues and cell types, which is incorporated herein by reference in its entirety. In some embodiments, the AAV vector comprises an ssDNA genome comprising a coding sequence for a Cas protein and a guide polynucleotide flanked by ITRs.

[1005] In some embodiments, the CRISPR-Cas protein system described herein is packaged in an AAV vector, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAVrh74. In some embodiments, the CRISPR-Cas protein system described herein is packaged in an AAV vector comprising an engineered capsid with tissue tropism, such as an engineered muscle tropism capsid. Tabebordbar et al., Cell 184:4919-4938 (2021) describes engineering of AAV capsids with tissue tropism by directed evolution, identifies a class of capsids containing RGD motifs, and systemic injection of MyoAAV can efficiently transduce primate muscles, which is incorporated herein by reference in its entirety.

[1006] lipid nanoparticles

[1007] Another aspect of the present disclosure relates to lipid nanoparticles (LNPs) comprising a CRISPR-Cas protein system described herein, wherein the LNP comprises a guide polynucleotide described herein and an mRNA encoding a Cas protein described herein.

[1008] Gillmore et al., N.Engl.J.Med., 385:493-502 (2021) describes the LNP delivery of the CRISPR-Cas system, lipid nanoparticles (LNPs) are composed of 4 lipids, including a proprietary ionizable lipid LP000001; DSPC; cholesterol and DMG-PEG2k, and the LNP suspension is formulated in an aqueous buffer of Tris, NaCl and sucrose, pH 7.4, which is incorporated herein by reference in its entirety. In some embodiments, in addition to RNA payload (Cas protein mRNA and guide polynucleotides), lipid nanoparticles (LNPs) also include four components: cationic or ionizable lipids, cholesterol, helper lipids and PEG-lipids. In some embodiments, the cation or ionizable lipids include cKK-E12, C12-200, ALC-0315, DLin-MC3-DMA, DLin-KC2-DMA, FTT5, Moderna SM-102, and Intellia LP01. In some embodiments, the PEG-lipids include PEG-2000-C-DMG, PEG-2000-DMG, or ALC-0159. In some embodiments, the helper lipids include DSPC. The components of LNPs are described in Paunovska et al., Nature Reviews Genetics 23: 265-280 (2022), and FDA-approved LNPs contain variants of four basic ingredients: cation or ionizable lipids, cholesterol, helper lipids, and polyethylene glycol (PEG) lipids, which are incorporated herein by reference in their entirety.

[1009] Lentiviral vectors

[1010] Another aspect of the present disclosure relates to a lentiviral vector comprising a CRISPR-Cas protein system as described herein, wherein the lentiviral vector comprises a guide polynucleotide as described herein and an mRNA encoding a Cas protein as described herein. In some embodiments, the lentiviral vector is pseudotyped with a homologous or heterologous envelope protein such as VSV-G. In some embodiments, the mRNA encoding the Cas protein is linked to an aptamer sequence.

[1011] RNP complex

[1012] Another aspect of the present disclosure relates to a ribonucleoprotein complex comprising a CRISPR-Cas protein system as described herein, wherein the ribonucleoprotein complex is formed by a guidance polynucleotide and a Cas protein as described herein. In some embodiments, the ribonucleoprotein complex can be delivered to eukaryotic cells, mammalian cells, or human cells by microinjection or electroporation. In some embodiments, the ribonucleoprotein complex can be packaged in virus-like particles and delivered to a mammal or human subject in vivo.

[1013] virus-like particles

[1014] Another aspect of the present disclosure relates to a virus-like particle (VLP) comprising the CRISPR-Cas protein system described herein, wherein the virus-like particle comprises a guide polynucleotide and a Cas protein described herein or a ribonucleoprotein complex consisting of the guide polynucleotide and the Cas protein.

[1015] Banskota et al. Cell 185(2):250-265(2022) reported the development and application of DNA-free virus-like particles (eVLPs) for efficient packaging and delivery of base editors or Cas9 ribonucleoprotein; Mangeot et al., Nature Communications 10(1):1-15(2019) used engineered mouse leukemia virus-like particles (Nanoblades) loaded with Cas9-sgRNA ribonucleoprotein to induce efficient genome editing in cell lines and primary cells (including human induced pluripotent stem cells, human hematopoietic stem cells and mouse bone marrow cells); Campbell, et al., Molecular Therapy 27: 151-163 (2019) utilizes a specialized extracellular vesicle called "gesicle" to effectively but transiently deliver Cas9 targeting HIV long terminal repeats (LTR) in the form of ribonucleoprotein. Gesicles are produced by expressing vesicular stomatitis virus glycoprotein and packaging protein (as its cargo), so there is no need for transgenic delivery, which allows for more precise control of Cas9 expression and Mangeot et al. Molecular Therapy, 19 (9): 1656-1666 (2011) reported that overexpression of the spike glycoprotein of vesicular stomatitis virus (VSV-G) in human cells induced the release of fusogenic vesicles called gesicles. Biochemical and functional studies have shown that glial cells bind proteins from production cells and can transport them to recipient cells. This protein transduction method allows direct transport of cytoplasmic, nuclear or surface proteins in target cells. These documents all describe engineered VLPs, which are incorporated herein by reference in their entirety.

[1016] In some embodiments, engineered virus-like particles (VLPs) are pseudotyped with homologous or heterologous envelope proteins, such as VSV-G. In some embodiments, the Cas protein is fused to a gag protein (e.g., MLVgag) via a cleavable linker, wherein cleavage of the linker in the target cell exposes an NLS between the linker and the Cas protein. In some embodiments, the fusion protein or conjugate comprises (e.g., from 5' to 3') a gag protein (e.g., MLVgag), one or more NESs, a cleavable linker, one or more NLSs, and a Cas protein, as described in Banskota et al. Cell 185(2):250-265(2022).

[1017] In some embodiments, the Cas protein is fused to a first dimerization domain that is capable of dimerizing or heterodimerizing with a second dimerization domain fused to a membrane protein, wherein the presence of a ligand promotes the dimerization and enriches the Cas protein or fusion protein or conjugate into the VLP as described in Campbell, et al., Molecular Therapy 27: 151-163 (2019).

[1018] cell

[1019] Another aspect of the present disclosure relates to cells comprising CRISPR-Cas protein systems as described herein.Cells (e.g., which can be used to produce cell-free systems) can be eukaryotic or prokaryotic.Examples of such cells include, but are not limited to, bacteria, archaebacteria, plants, fungi, yeasts, insects, and mammalian cells, such as lactobacilli, lactococci, bacillus (e.g., bacillus subtilis), Escherichia (e.g., Escherichia coli), Clostridium, Saccharomyces, or Pichia (e.g., Saccharomyces cerevisiae or Pichia pastoris), Kluyveromyces lactis, Salmonella typhimurium, Drosophila cells, Caenorhabditis elegans cells, African clawed frog cells, SF9 cells, C129 cells, 293 cells, Neurospora, and immortalized mammalian cell lines (e.g., Hela cells, bone marrow cell lines, and lymphoid cell lines).

[1020] In some embodiments, the cell is a prokaryotic cell, such as a bacterial cell, such as escherichia coli. In some embodiments, the cell is a eukaryotic cell, such as a mammalian cell or a human cell. In some embodiments, the cell is a primary eukaryotic cell, a stem cell, a tumor / cancer cell, a circulating tumor cell (CTC), a blood cell (for example, T cell, B cell, NK cell, Tregs etc.), a hematopoietic stem cell, a specialized immune cell (such as tumor infiltrating lymphocytes or tumor suppressor lymphocytes), a stromal cell (such as cancer associated fibroblasts etc.) in a tumor microenvironment. In some embodiments, the cell is the brain or neuronal cell (for example, neuron, astrocyte, microglia, retinal ganglion cell, rod / cone cell etc.) of a central or peripheral nervous system.

[1021] Target nucleic acid or target DNA

[1022] In some embodiments of the present invention, the target nucleic acid is target DNA.

[1023] The CRISPR-Cas protein system described herein can be used to target one or more target nucleic acid molecules, such as target nucleic acid molecules present in a biological sample, an environmental sample (e.g., a soil, air, or water sample), and the like.

[1024] In some embodiments of the present invention, the target nucleic acid is a disease or condition-associated gene. In some embodiments of the present invention, the target nucleic acid is a disease-associated gene. In some embodiments of the present invention, the disease-associated gene is a pathogenic gene that directly causes the disease. In some embodiments of the present invention, the disease-associated gene is an abnormal gene that directly causes the disease or a gene whose expression is abnormal. For example, an adverse mutation occurs in the gene, leading to the occurrence of the disease. For another example, excessive or low expression of the gene leads to the occurrence of the disease.

[1025] In some embodiments of the present invention, the disease or disorder is a hematological disease or disorder, an ophthalmic disease or disorder, a nervous system disease or disorder, a respiratory system disease or disorder, a liver disease or disorder, a metabolic system disease or disorder, cancer, or an infectious disease.

[1026] In a specific embodiment of the present invention, the disease and / or condition is selected from the group consisting of hemophilia A, Best vitelliform macular dystrophy, B-cell acute lymphoblastic leukemia, hemophilia B, CDKL5 deficiency, CLN2disease, Niemann-Pick disease type C, Dravet syndrome, FOXG1 syndrome, GM1 gangliosidosis, GM2 gangliosidosis, HIV infection, HSV infection, Usher syndrome type IB, Usher syndrome type IIA, mucopolysaccharidosis type IIIA, mucopolysaccharidosis type IIIB, Gaucher disease type III, mucopolysaccharidosis type II, type II diabetes mellitus, type IV mucopolysaccharidosis, type I Gaucher disease, mucopolysaccharidosis type I, type I diabetes mellitus, type I Usher syndrome, KCNQ2 epileptic encephalopathy, Leber hereditary optic neuropathy, Leigh syndrome, Prader-Willi syndrome, SLC13A5 deficiency, X-linked myotubular myopathy, X-linked retinoschisis, X-linked retinitis pigmentosa, alpha-1 antitrypsin deficiency, alpha-mannosidosis, alpha-thalassemia, beta-thalassemia, Alzheimer's disease, Budd-Bieder syndrome, albicans punctata, leukocyte adhesion deficiency type I, galactosemia, bladder cancer, overactive bladder, phenylketonuria, nasopharyngeal carcinoma, Bietti's crystalline dystrophy, pyruvate kinase deficiency, erectile dysfunction, Recessive congenital ichthyosis, adult glucan body disease, traumatic arthritis, homozygous familial hypercholesterolemia, fragile X syndrome, thalassemia, hypophosphatasia, epilepsy, multiple myeloma, multiple system atrophy, frontotemporal dementia, catecholamine-sensitive polymorphic ventricular tachycardia, Fabry disease, Fanconi anemia, aromatic amino acid decarboxylase deficiency, radiation-induced xerostomia, non-Hodgkin's lymphoma, non-muscle invasive bladder cancer, non-alcoholic fatty liver disease, non-small cell lung cancer Lung cancer, hypertrophic cardiomyopathy, hypertrophic scarring, obesity, Charcot-Marie-Tooth disease type 1A, Charcot-Marie-Tooth disease type 2A, pulmonary hypertension, Friedreich's ataxia, peritoneal cancer, liver cancer, hepatocellular carcinoma, dry age-related macular degeneration, Sjögren's syndrome, hyperuricemia, hyperlipidemia, Gaucher disease, autism spectrum disorder, osteoarthritis, bone marrow failure syndrome, citrullinemia type 1, coronary artery disease, cystinosis, melanoma, Huntington's disease, amyotrophic lateral sclerosis, urge urinary incontinence, acute intermittent urinary incontinence Porphyria, acute lymphoblastic leukemia, spinocerebellar ataxia, spinal muscular atrophy with respiratory distress type 1, spinal muscular atrophy, familial Tay-Sachs disease, methylmalonic acidemia, thyroid cancer, pseudohypertrophic muscular dystrophy, anaplastic astrocytoma, intermittent claudication, junctional epidermolysis bullosa, glioma, glioblastoma, corneal transplant rejection, colorectal cancer, progressive multifocal leukoencephalopathy, progressive familial intrahepatic cholestasis, giant axonal neuropathy, Canavan disease, cocaine addiction,Krabbe disease, Crigler-Najjar syndrome, oral cancer, Happy Marionette syndrome, diffuse intrinsic pontine glioma, Lafora disease, rheumatoid arthritis, sickle cell disease, lymphedema, ovarian cancer, chronic lymphocytic leukemia, chronic granulomatous disease, anemia of chronic kidney disease, chronic pain, chronic hepatitis B, Menkes disease, cystic fibrosis, Netherton syndrome, ornithine transcarbamylase deficiency, Parkinson's disease, Pompe disease, uveitis, prostate cancer, vestibular schwannoma, myotonic dystrophy, ankylosing spondylitis, castration-resistant prostate cancer, glaucoma, achromatopsia, ischemic heart failure, lysosomal storage diseases, sarcoma, breast cancer, Rett syndrome Syndrome, triple-negative breast cancer, Sandhoff disease, color blindness, heart failure with reduced ejection fraction, neuronal ceroid lipofuscinosis, adrenoleukodystrophy, renal cell carcinoma, wet age-related macular degeneration, eczema, thrombocytopenia with immunodeficiency syndrome, esophageal cancer, optic neuropathy, optic atrophy, retinal vein occlusion, retinitis pigmentosa, rhodopsin-mediated autosomal dominant retinitis pigmentosa, ependymoma, fallopian tube cancer, bilateral vestibulopathy, Stargardt's disease, diabetic macular edema, diabetic neuropathy, diabetic retinopathy, diabetic peripheral neuropathy, diabetic foot, glycogen storage disease, glycogen storage disease type Ia, glycogen storage dyslipidemia type IIb, atopic dermatitis, hearing loss, hearing impairment, head and neck cancer, head and neck squamous cell carcinoma, Wilson's disease, stable angina, Ussher syndrome, choroideremia, congenital amaurosis, congenital adrenal hyperplasia, cardiomyopathy, angina pectoris, heart failure, novel coronavirus infection, pleural mesothelioma, acne vulgaris, severe combined immunodeficiency, critical limb ischemia, oculopharyngeal muscular dystrophy, pancreatic cancer, graft-versus-host disease, hereditary retinal dystrophy, hereditary angioedema, hepatitis B, metachromatic leukodystrophy, psoriatic arthritis, recessive dystrophic epidermolysis bullosa, infantile malignant osteopetrosis , dystrophic epidermolysis bullosa, morphea, primary immunodeficiency, heterozygous familial hypercholesterolemia, limb-girdle muscular dystrophy type 2B, limb-girdle muscular dystrophy type 2C, limb-girdle muscular dystrophy type 2D, limb-girdle muscular dystrophy type 2E, limb-girdle muscular dystrophy type 2I, limb-girdle muscular dystrophy type 2L, limb ischemic disease, lipoprotein lipase deficiency, severe congenital neutropenia, wrinkles, stroke, sciatica, schizophrenia, depression, drug addiction, autism, idiopathic pulmonary fibrosis, transthyretin (ATTR) amyloidosis, AATD liver disease and AATD lung disease, and elevated blood lipids.

[1027] In a specific embodiment of the present invention, the transthyretin (ATTR) amyloidosis-related genes include but are not limited to ATTR;

[1028] The genes related to Leber hereditary optic neuropathy include but are not limited to MT-ND4;

[1029] The AATD liver disease related genes include but are not limited to AATD;

[1030] The AATD lung disease related genes include but are not limited to AATD;

[1031] The graft-versus-host disease related genes include but are not limited to thymidine kinase gene;

[1032] The genes related to hereditary retinal dystrophy include but are not limited to RPE65;

[1033] The spinal muscular atrophy-related genes include but are not limited to SMN1;

[1034] The osteoarthritis related genes include but are not limited to TGF-β1;

[1035] The related genes of hemophilia A include but are not limited to factor VIII;

[1036] The related genes of hemophilia B include but are not limited to factor IX;

[1037] The cystic fibrosis related genes include but are not limited to CFTR;

[1038] The Parkinson's disease-related genes include but are not limited to Gad1, Gad2, PTBP1 and REST;

[1039] The Usher syndrome related genes include but are not limited to USH2A;

[1040] The genes related to α-thalassemia, β-thalassemia, and sickle cell disease include but are not limited to BCL11A, HBG, HBA, and HBB;

[1041] The pulmonary hypertension related genes include but are not limited to eNOS;

[1042] The Stargardt disease-related genes include but are not limited to ABCA4;

[1043] The genes related to age-related macular degeneration include but are not limited to VEGFA and VEGFR;

[1044] The glaucoma-related genes include but are not limited to AQP1;

[1045] The idiopathic pulmonary fibrosis related genes include but are not limited to CTGF;

[1046] The Alzheimer's disease related genes include but are not limited to NGF;

[1047] The coronary heart disease related genes include but are not limited to VEGFA and bFGF;

[1048] The genes related to anemia in chronic kidney disease include but are not limited to EPO;

[1049] The related genes of congenital amaurosis include but are not limited to RPE65;

[1050] The retinitis pigmentosa related genes include but are not limited to PDE6B;

[1051] The phenylketonuria related genes include but are not limited to PAH;

[1052] The epilepsy-related genes include but are not limited to GAT1;

[1053] The genes related to increased blood lipids include but are not limited to PCSK9.

[1054] Non-limiting examples of such target nucleic acids also include those listed in U.S. Provisional Patent Applications 61 / 736,527 and 61 / 748,427, filed on December 12, 2012 and January 2, 2013, respectively, and International Application PCT / US2013 / 074667, filed on December 12, 2013, all of which are incorporated herein by reference.

[1055] In some embodiments, the target nucleic acid is a reporter gene. Examples of reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), β-galactosidase, β-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP).

[1056] Therapeutic applications

[1057] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a Cas protein as described herein, a guiding polynucleotide as described herein, an inactivated variant of a Cas protein as described herein, a fusion protein or conjugate as described herein, a nucleic acid as described herein, a CRISPR-Cas protein system as described herein, a vector system as described herein, a delivery system as described herein, or a cell as described herein. The pharmaceutical composition may comprise, for example, an AAV vector encoding a Cas protein or an inactivated variant of a Cas protein and a guiding polynucleotide as described herein. The pharmaceutical composition may comprise, for example, a lipid nanoparticle comprising a guiding polynucleotide as described herein and an mRNA encoding a Cas protein. The pharmaceutical composition may comprise, for example, a lentiviral vector comprising a guiding polynucleotide as described herein and an mRNA encoding a Cas protein. The pharmaceutical composition may comprise, for example, a virus-like particle comprising a guiding polynucleotide and a Cas protein as described herein or a ribonucleoprotein complex formed by the guiding polynucleotide and the Cas protein.

[1058] Another aspect of the present disclosure relates to the use of a Cas protein as described herein, a guide polynucleotide as described herein, an inactivated variant of a Cas protein as described herein, a fusion protein or conjugate as described herein, a nucleic acid as described herein, a CRISPR-Cas protein system as described herein, a vector system as described herein, a delivery system as described herein, a cell as described herein, a pharmaceutical composition as described herein, or a kit as described herein for cutting or editing a target nucleic acid in a mammalian cell.

[1059] Another aspect of the present disclosure relates to the use of a Cas protein as described herein, a guide polynucleotide as described herein, an inactivated variant of a Cas protein as described herein, a fusion protein or conjugate as described herein, a nucleic acid as described herein, a CRISPR-Cas protein system as described herein, a vector system as described herein, a delivery system as described herein, a cell as described herein, a pharmaceutical composition as described herein, or a kit as described herein for any of the following: cleaving one or more target nucleic acid molecules or causing nicks in one or more target nucleic acid molecules, activating or upregulating the expression of one or more target nucleic acid molecules, activating or inhibiting the transcription of one or more target nucleic acid molecules, inactivating one or more target nucleic acid molecules, visualizing, labeling or detecting one or more target nucleic acid molecules, binding one or more target nucleic acid molecules, transporting one or more target nucleic acid molecules, and masking one or more target nucleic acid molecules.

[1060] Another aspect of the present disclosure relates to the use of a Cas protein as described herein, a guide polynucleotide as described herein, an inactivated variant of a Cas protein as described herein, a fusion protein or conjugate as described herein, a nucleic acid as described herein, a CRISPR-Cas protein system as described herein, a vector system as described herein, a delivery system as described herein, a cell as described herein, a pharmaceutical composition as described herein, or a kit as described herein to modify one or more target nucleic acid molecules, wherein the modification of one or more target nucleic acid molecules comprises one or more of the following: nucleic acid base substitution, nucleic acid base deletion, nucleic acid base insertion, fragmentation of the target nucleic acid, nucleic acid methylation, and nucleic acid demethylation.

[1061] Another aspect of the present disclosure relates to the use of a Cas protein as described herein, a guide polynucleotide as described herein, an inactivated variant of a Cas protein as described herein, a fusion protein or conjugate as described herein, a nucleic acid as described herein, a CRISPR-Cas protein system as described herein, a vector system as described herein, a delivery system as described herein, a cell as described herein, a pharmaceutical composition as described herein, or a kit as described herein in the diagnosis, treatment or prevention of a disease or disorder associated with a target nucleic acid.

[1062] Another aspect of the present disclosure relates to the use of a Cas protein as described herein, a guide polynucleotide as described herein, an inactivated variant of a Cas protein as described herein, a fusion protein or conjugate as described herein, a nucleic acid as described herein, a CRISPR-Cas protein system as described herein, a vector system as described herein, a delivery system as described herein, a cell as described herein, a pharmaceutical composition as described herein, or a kit as described herein in the preparation of a medicament for diagnosing, treating or preventing a disease or disorder associated with a target nucleic acid.

[1063] In some embodiments, the pharmaceutical composition is delivered to a human subject in vivo. The pharmaceutical composition can be delivered by any effective route. Exemplary routes of administration include, but are not limited to, intravenous infusion, intravenous injection, intraperitoneal injection, intramuscular injection, intratumoral injection, subcutaneous injection, intradermal injection, intraventricular injection, intravascular injection, intracerebellar injection, intraocular injection, subretinal injection, intravitreal injection, intracameral injection, intratympanic injection, intranasal administration, and inhalation.

[1064] Diagnostic applications

[1065] Another aspect of the present disclosure relates to an in vitro composition comprising a CRISPR-Cas protein system described herein and a labeled detector DNA that is incapable of hybridizing to a guide polynucleotide described herein.

[1066] Another aspect of the present disclosure relates to the use of the CRISPR-Cas protein system described herein for detecting a target nucleic acid in a nucleic acid sample suspected of containing the target nucleic acid.

[1067] Another aspect of the present disclosure relates to the use of the CRISPR-Cas protein system described herein for detecting a target nucleic acid in a nucleic acid sample comprising the target nucleic acid.

[1068] In some embodiments, the target nucleic acid detected is a target RNA.

[1069] In some embodiments, the target nucleic acid to be detected is a target DNA. In some embodiments, the method for detecting the target DNA comprises a Cas protein fused to a fluorescent protein or other detectable marker and a guide polynucleotide comprising a guide sequence specific for the target DNA. The binding of the Cas protein to the target DNA can be visualized by microscopy or other imaging methods.

[1070] In some embodiments, the method for detecting a target nucleic acid in a cell-free system results in the production of a detectable label or enzyme activity. For example, by using a Cas protein, a guide polynucleotide comprising a guide sequence specific for the target nucleic acid, and a detectable label, the target nucleic acid will be recognized by the Cas protein. The binding of the Cas protein to the target nucleic acid triggers its DNase activity, which results in the cleavage of the target nucleic acid and the detectable label.

[1071] In some embodiments, the detectable label is a DNA connected to a fluorescent probe and a quencher. The complete detectable DNA is connected to the fluorescent probe and the quencher to inhibit fluorescence. After the detectable DNA is cut by the Cas protein, the fluorescent probe is released from the quencher and shows fluorescent activity. This method can be used to determine whether the target DNA is present in a lysed cell sample, a lysed tissue sample, a blood sample, a saliva sample, an environmental sample (such as a water, soil or air sample), or other lysed cells or cell-free samples. This method can also be used to detect pathogens, such as viruses or bacteria, or to diagnose disease states, such as cancer.

[1072] In some embodiments, detection of a target nucleic acid aids in diagnosing a disease and / or pathological condition, or the presence of a viral or bacterial infection.

[1073] Example

[1074] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.

[1075] Example 1. Preparation and purification of Cas protein

[1076] 1. Vector Construction

[1077] The pET28a vector plasmid was double-digested with BamHI and XhoI, and the linearized vector was recovered by agarose gel electrophoresis. The DNA fragment encoding the Cas protein of the present disclosure was obtained and the homologous recombination method (NEB, Gibson The master mix was inserted into the cloning region of the pET28a vector to construct a recombinant vector. The reaction mixture was transformed into Stbl3 competent cells, coated on kanamycin sulfate-resistant LB plates, and cultured overnight at 37°C. Clones were then selected and sequenced.

[1078] Positive clones with correct sequences were picked and cultured overnight. The plasmids were extracted and transformed into expression strain Rosetta (DE3). The plates were spread with kanamycin sulfate and cultured at 37°C overnight.

[1079] 2. Protein Expression

[1080] A single clone was picked and inoculated into 5 ml of LB culture medium containing kanamycin sulfate and cultured at 37°C overnight.

[1081] The cells were inoculated into 500 ml of LB culture medium containing kanamycin sulfate at a ratio of 1:100, cultured at 220 rpm and 37°C to an OD of 0.6, and IPTG was added to a final concentration of 0.2 mM, and induced at 16°C for 24 h.

[1082] The cells were rinsed with 15 ml PBS, collected by centrifugation, and ultrasonically disrupted with lysis buffer. The cells were centrifuged at 10,000 g for 30 min to obtain the supernatant containing the recombinant protein. The supernatant was filtered through a 0.45 μm filter membrane and then purified by column purification.

[1083] 3. Protein purification

[1084] The 6 His residues at the N-terminus were used as purification tags, purified by IMAC, and purified by chromatography to obtain the recombinant protein of the Cas protein (the recombinant protein structure is His tag-NLS-Cas-NLS-NLS). The purified recombinant protein was detected by SDS-PAGE electrophoresis.

[1085] Example 2. Determination of PAM sequences recognized by Cas proteins

[1086] In this example, a sgRNA (single guide RNA) containing a specific guide sequence and the recombinant protein purified in Example 1 were mixed to cut the in vitro cleavage substrate (containing a spacer sequence and a 7nt random sequence), incubated at 37°C, purified, and a library was constructed. NGS sequencing and analysis were performed to determine the PAM sequence recognized by the Cas protein.

[1087] The designed in vitro cleavage substrate sequence is as follows:

[1088] In the sequence, N represents any of A, T, C, and G.

[1089] Take the cleavage substrate to the sequencing company for PCR-Free library construction and NGS sequencing.

[1090] Preparation of sgRNA

[1091] An sgRNA containing a guide sequence and a DR sequence (or further containing the corresponding tracrRNA sequence and a 5'-GAAA-3' linker sequence at the 5' end) was synthesized by in vitro transcription. The transcript was precipitated with LiCl and purified. The guide sequence was GUGAGCAAGGGCGAGGAGCUGUUC or CGCAAUGAUGAUCUCCGAGCCGUUCC.

[1092] PAM library excision, NGS sequencing, and NGS results analysis: Reference (A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope. PLoS biology, 2020, 18(3), e3000686.) The method was analyzed using WebLogo software to obtain the captured 7nt random sequence. The PAM sequence was thus identified.

[1093] Example 3. Testing the cleavage activity of Cas proteins in vitro

[1094] In this example, the sgRNA and recombinant protein in the previous examples were mixed, and the target DNA (dsDNA or ssDNA) was cut in vitro. The cut products were analyzed by gel electrophoresis to show the cutting effect of the Cas protein.

[1095] Example 5. Editing activity test in eukaryotic cells

[1096] The sgRNA (the guide sequence is replaced with a guide sequence targeting human cells) in the above example and the recombinant protein were mixed and incubated to obtain RNP, which was then transfected into 293T cells. After overnight transfection, fresh culture medium was replaced and cultured.

[1097] DNA extraction, PCR amplification, and Sanger sequencing: After 72 h of culture, cells were washed with PBS and then lysed with 100 μl of cell lysis buffer to obtain a lysate containing genomic DNA. The region near the target sequence was amplified from the genomic DNA, and the PCR product was sent to a sequencing company for Sanger sequencing.

[1098] Sequencing data analysis: TIDE analysis is performed on the sequencing peak graph and gRNA guide sequence related information to obtain the editing efficiency of the target nucleic acid.

Claims

1. Cas protein, characterized in that The amino acid sequence of the Cas protein comprises or is an amino acid sequence that is at least 50% identical to any one of SEQ ID NOs: 1-461. Alternatively, the at least 50% identity is at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identity; Optionally, the Cas protein retains the function of the protein shown in any one of SEQ ID NOs: 1-461; Optionally, the PAM sequence (5'→3') recognizable by the Cas protein is selected from any one or more of the following: A, C, T, G, TA, TC, GN, AA, AG, TG, AN, GG, CG, TN, NT, NG, GT, NA, CC, AC, GC, AT, CT, GA, TT, CN, NC, CA, NTN, ANN, TTN, ATC, NAC, AGA, TGC, TCT, NGN, CGC, NTC, GCA, TCG, TTT, CCG, GGG, NAG, ACA, CGG, CNG, ACN, GTG, CNT, TTG, TCN, GGT, TNC, CCN, CGT, TGG, CGA, NGG, TCC, AGT, NCA, CAN, TCA, NNG, TAC, CCT, NTG, CGN, TGN, CAT, NGC, GNG, GNC, NNA, GAA, TTC, CTT, ATA, TAT, GCT, NCC, TTA, AGN, GNN, CAA, CAC, AGG, NTT, ANG, GNA, GTT, NGA, TAA, GTA, GGN, GNT, NCG, ATT, CCA, CNN, AAA, AAC, ATN, GAG, CTG, ACG, NAA, TAN, NAT, CNA, GCN, GTC, NCN, CTN, CNC, ANT, NNC, CAG, NAN, ATG, NCT, CCC, AAN, TGT, TNA, ACC, GAT, ACT, AAT, GGA, GAN, ANC, GAC, NNT, CTA, TNN, GCG, GTN, TNT, AAG, TAG, NGT, NTA, ANA, CTC, GCC, TGA, GGC, AGC, TNG, <h2 style=";text-align:left;direction:ltr">NGAA、GANC、GCNC、NTNT、TGGG、AAGG、AAGN、NTNN、TCGT、CNTG、NTGG、CCGN、A TAT、TGCA、NGGT、TGNT、NNTG、NCCG、ACAT、GNTG、CGCG、GACN、NTCG、TCNG、CT GC, TNNC, GGTN, CGNN, TCCA, AGCN, TNAG, GGAC, GATC, AANA, NATG, CCAG, NAAT, TCNT, CACT, CGGC, CGAN, CNCA, ATNT, NNNG, NGCT, CTGG, GGAN, NTNC, ATTC, AATG、CNTC、TGGN、NATC、GTCG、ACNC、GCNN、GACT、CTNT、NCTT、NAGG、NANC、C TTA、GTCT、ANAG、NGCN、CNNA、TCAG、ACAC、NCGG、TNNT、CAAG、ACCT、CCCA、GT NC, ANTC, GACC, AACG, TTAA, TCCG, CGCC, NCCN, TTNA, NCNT, NGCA, AGNN, AATC, GGGA, GNAN, NAGA, CGNA, GTAT, GTNA, ATNC, ACNA, GGAA, NTCC, GGCG, AATN, <h2 style=";text-align:left;direction:ltr">CNNT、AGGC、GCGN、GTGC、TTGA、AAGC、GAAG、ATNG、TGCT、TACT、CTAN、GGCT、GN GC、GTCN、CGAA、CNAC、GCCT、TAGG、ANGC、TNAA、GANT、NCNA、NCCT、AGAN、GTAA、 TTTN, ATGA, TGNA, CANAC, ACGA, CCAC, CCGG, CTNG, CNGN, GGTA, NGNC, GTTT, CTAA, TNCT, CTGN, NGAC, TGTA, TANN, GCNT, GCTC, CNCG, AAAAN, CCNT, GANA, CACA CTNA,ANTN,TTNT,CCTG,TNTT,CANA,NTAN,CACG,GGAT,TTTC,GNCG,TACA,GTAC,GAGC,ACNN,ATGG,AANT,ATCC,ACCG,AGNC,TGTT,NCAT,ATTA,GNTT,GAGN TNAC,GCCG,NTNG,GTGG,GNGN,ACCA,NTAA,ACTN,NCTG,NCTA,TTTT,GCNG,NTAG,CAAA,GGNA,CNTN,TTAG,TCTG,NCTN,TATG,GCGT,TANT,GGGT,NACN,ACTG CCNG、GNNT、CCAT、GNTA、NANT、TACN、TGTN、ATCT、NCAN、TNGG、CNNN、AAGT、AT TN、GGNN、CAGC、CGTN、GCCC、GCTT、CNAT、NANA、CCNN、GNGA、TNGN、GCAG、CGNG、 CCTT, NGAG, NCNG, AANG, GGTC, ACTC, TGAA, NAGN, NNCA, ACGG, TGAC, TCCN, ANNN, TCGN, TAAN, CAGG, TTAN, NGAN, NTGC, CCNC, TNTN, ATGN, GTGN, GCAT, NNGN NNCC, CCNA, CNAG, GNAC, CGNT, TTCN, TAGN, ANCT, NATN, GTGA, TNGT, CTAT, CCCG, TNCA, NGTA, NNGA, CGTG, TAAT, CGCA, NNCG, NGTC, NAGT, GNAT, TNTC, NCGC NGGN, CATN, GTTN, AGTA, GNNG, TTNN, TGNC, NAAA, TNCC, CACC, CTCT, TTGN, GCTA, NTTT, TGAN, TNAN, NGAT, CCTN, GAAT, GTCA, NTCN, GCCA, ANTG, TGGC, CAAC<h2 style=";text-align:left;direction:ltr">TTTA, TGTC, CGGA, NCGN, AGNT, NCGA, ANCG, ACAA, TAGT, CGAG, NCAA, AATA, AGGG, GNGT, CAGA, AGGT, GGGG, ANAC, TGGT, GTGT, GNCA, GTTA, NGTT, TNNG, NCAG, CACN, GCAN, GAAC, NCCA, TTCC, NCNN, GNNN, AN GT, NTNA, CCCT, GNAA, TTNG, GTNN, GGNG, TCTA, NCAC, GANG, TTCG, CCTC, CNGG, ANNA, TCAN, ATCG, NTGA, CGTA, TTAC, GCTN, GCTG, NGTG, TCCC, CANN, NNNA, TAGA, ACGT, AGAT, GATG, GCCN, TGNG, GCGC, CCGA GNCN, NTTG, NNAT, TNCG, NANG, GGTG, NCCC, GNCC, CAAT, CGCN, CNGA, NTTC, TTCT, NGGA, AGTC, CNNC, NACG, AGTN, NANN, ACAG, GNCT, TACC, CNTA, TGTG, CATC, GACA, TCTT, NTCT, CTGA, AGGA, GATA, TNAT, CC TA, GGAG, ANCC, AANC, GTAN, GCNA, TGNN, TANC, GNTN, AGCG, CTAG, NNAA, AGTT, CTAC, TACG, TTNC, TNTA, ANTT, ATAC, TCCT, TCAC, NGGC, NTTN, NNTC, CANT, ATAA, TGCC, CTCC, TNNA, GTNG, ACGN, GGCA, AAAAG <h2 style=";text-align:left;direction:ltr">TTGT, NGNA, NAAN, TATN, CGGG, CATA, ATGC, ACGC, ACCN, ATTT, TCNA, TNGC, NACA, NACC, CTCN, GGCC, TANG, AGAA, TNGA, TAGC, CAGN, GGCN, ANNT, NNNC, TC AT, CATT, TAAA, ATGT, TGAG, CGCT, TCGG, GCAC, GTAG, NTCA, NATT, ANTA, CCCN, ACTA, AAAA, GAAN, TATT, NNAC, TGAT, GGGN, CCAA, GNGG, CCAN, GTCC, NNCT AGNG、CNTT、CNCT、GANN、GGTT、AGCT、CATG、NTAC、TNCN、NNTN、TGGA、GATT、A GCA、TAAG、GCGA、ACTT、ANGN、NTGN、AACN、AACT、TCAA、NTAT、TCGA、NCTC、NN GG, ANGG, NNTT, GTNT, CTNN, CGGN, TAAC, GGNC, GAAA, ACNG, GNAG, TTGG, CTTC, CNGT, TNNN, TNTG, GTTG, TCNN, CGGT, GAGA, CNNG, NCNC, GAGG, AGCC, ATNN, NNNT, AGAC, AACC, ANNC, ANNG, ACAN, GTTC, TATA, GNTC, NCGT, NGNT, CGTC, CCGC, CGAC, GACG, ATTG, GNNC, CNAA, TATC, AGNA, CTNC, TTCA, ANCA, ACCC, AG TG、CCGT、ANAT、CTGT、GGGC、NTTA、NAAG、AANN、CNAN、NNCN、ANAA、ANAN、CTT G、NGNN、AGAG、TANA、TCNC、GCAA、NGNG、NAGC、NATA、ATCN、CGTT、CNGC、GATN、 NNTA,AAGA,CTTT,AAAC,AGGN,ACNT,NTGT,CTTN,ATCA,NACT,NNAG,NGTN,NAAC,TGCG,GGNT,ATAN,TTGC,ANCN,CCCC,ANGA,NGCG,TCTC,CTCG,ATNA,AA TT, NNAN, NNGT, TCGC, ATAG, CAAN, AACA, TTAT, CAGT, GNNA, TGCN, GCGG, NGGG, CANG, TTTG, GAGT, AAAT, CTCA, CNCN, CNCC, TCTN, CGNC, NGCC, CGAT, NNGC; Preferably, the Cas protein can form a complex with the guide polynucleotide, or the Cas protein can specifically bind to the target nucleic acid with the guide polynucleotide; More preferably, the amino acid sequence of the Cas protein comprises or is an amino acid sequence as shown in any one of SEQ ID NOs: 1-461.

2. A guide polynucleotide, characterized in that It comprises (i) a direct repeat sequence having at least 50% identity to any one of SEQ ID NOs: 462-922, and (ii) a guide sequence engineered to hybridize to a target nucleic acid; the direct repeat sequence is linked to the guide sequence, and the guide polynucleotide is capable of forming a complex with the Cas protein and guiding the complex to sequence-specific binding to the target nucleic acid; Preferably, the Cas protein is the Cas protein according to claim 1; Optionally, the guide sequence comprises 15-60 nucleotides, Optionally, the guide sequence hybridizes to the target nucleic acid, and the guide sequence has no more than one nucleotide mismatch with the target nucleic acid; Optionally, the nucleotide sequence of the direct repeat sequence is shown in any one of SEQ ID NOs: 462-922; Optionally, the guide polynucleotide further comprises tracrRNA; Optionally, the tracrRNA sequence is connected to the direct repeat sequence; Optionally, the tracrRNA comprises 10-200 nucleotides; Optionally, the guide sequence is located at the 3' end of the direct repeat sequence; Optionally, the guide sequence is located at the 5' end of the direct repeat sequence; Optionally, the tracrRNA sequence is located at the 5' or 3' end of the direct repeat sequence; Optionally, the tracrRNA sequence is at least 50% identical to any one of SEQ ID NOs: 923-1183.

3. Cas protein inactivated variant, characterized in that The Cas protein inactivated variant is a nuclease activity inactivated variant of the Cas protein according to claim 1; Optionally, the Cas protein inactivated variant is a dead Cas protein inactivated variant or a nickase Cas protein inactivated variant; Optionally, the inactivated variant of the Cas protein is an inactivated Ruvc domain of the Cas protein.

4. A fusion protein or conjugate, characterized in that The fusion protein or conjugate comprises the following elements: (1) the Cas protein according to claim 1, or the inactivated variant of the Cas protein according to claim 3; and (2) homologous or heterologous functional domains; Optionally, the homologous or heterologous functional domain is selected from one or more of the following: subcellular localization signal, DNA binding domain, protease domain, transcription activation domain, transcription repression domain, nuclease domain, deaminase domain, uracil DNA glycosylase domain (UDG), uracil DNA glycosylase inhibitory domain (UGI), methylase, demethylase, transcription release factor, histone acetylase domain, histone deacetylase domain, DNA ligase, affinity tag, reporter tag, affinity domain and reporter domain; Optionally, the nuclease domain comprises a polypeptide having ssDNA cleavage activity and / or a polypeptide having dsDNA cleavage activity; Optionally, the Cas protein or inactivated variant is directly or indirectly connected to the homologous or heterologous functional domain; preferably, the direct connection is covalent connection, and the indirect connection is connected through an amino acid linker or a non-amino acid linker; Optionally, the homologous or heterologous functional domain is fused or conjugated at the N-terminus, C-terminus or internally relative to the Cas protein or inactivated variant.

5. An isolated nucleic acid, characterized in that The nucleic acid encodes the Cas protein according to claim 1, the inactivated variant of the Cas protein according to claim 3, or the fusion protein or conjugate according to claim 4; Optionally, the nucleic acid is codon-optimized for expression in a cell; Optionally, the nucleic acid is codon-optimized for expression in prokaryotes; Optionally, the nucleic acid is codon-optimized for expression in eukaryotic cells; Optionally, the nucleic acid is codon-optimized for expression in a eukaryote, a mammal such as a human or non-human mammal, a plant, an insect, a bird, a reptile, a rodent (e.g., mouse, rat), a fish, a worm / nematode, or a yeast.

6. A CRISPR-Cas protein system, characterized in that The CRISPR-Cas protein system comprises: a. The Cas protein of claim 1, the guide polynucleotide of claim 2, the inactivated Cas protein variant of claim 3, the fusion protein or conjugate of claim 4, or the nucleic acid of claim 5; and b. a guide polynucleotide, or a polynucleotide sequence encoding the guide polynucleotide; The Cas protein functional domain or the fusion protein or conjugate forms a complex with the guide polynucleotide; the guide polynucleotide comprises a guide sequence, and the guide sequence is engineered to guide the sequence-specific binding of the complex to the target nucleic acid. Optionally, the guide polynucleotide comprises a direct repeat sequence linked to the guide sequence, preferably, the direct repeat sequence has at least 50% identity compared to any one of SEQ ID NOs: 462-922; Optionally, the guide sequence comprises 15-35 nucleotides, and / or the guide sequence hybridizes to the target nucleic acid, and the guide sequence and the target nucleic acid are 90%-100% complementary, preferably with no more than one nucleotide mismatch; Optionally, the guide sequence comprises 15-60 nucleotides; Optionally, the guide sequence hybridizes to the target nucleic acid; Optionally, the guide sequence is mismatched with the target nucleic acid by no more than one nucleotide; Optionally, the guide polynucleotide further comprises a tracrRNA; optionally, the tracrRNA sequence is linked to the direct repeat sequence; optionally, the tracrRNA comprises 10-200 nucleotides; Optionally, the guide sequence is located at the 3' end of the direct repeat sequence; Optionally, the guide sequence is located at the 5' end of the direct repeat sequence; Optionally, the tracrRNA sequence is located at the 5' or 3' end of the direct repeat sequence; Optionally, the target nucleic acid is DNA or RNA, preferably dsDNA or ssDNA; Optionally, the DNA is eukaryotic DNA; preferably, the eukaryotic DNA is non-human mammal DNA, non-human primate DNA, human DNA, plant DNA, insect DNA, bird DNA, reptile DNA, rodent DNA, fish DNA, worm / nematode DNA or yeast DNA; Optionally, the target nucleic acid is a disease or disorder-related gene or a signal transduction biochemical pathway-related gene, or the target nucleic acid is a reporter gene; for example, the disease or disorder is a blood system disease or disorder, an ophthalmic disease or disorder, a nervous system disease or disorder, a respiratory system disease or disorder, a liver disease or disorder, a metabolic system disease or disorder, cancer or an infectious disease; further preferably, the target nucleic acid is a disease or disorder-related gene, and the disease or disorder is selected from: hemophilia A, Best vitelliform macular dystrophy, B cell acute lymphoblastic leukemia, hemophilia B, CDKL5 deficiency, CLN2 disease, Niemann-Pick disease type C, Dravet syndrome, FOXG1 syndrome, GM1 gangliosidosis, GM2 gangliosidosis, HIV infection, HSV infection, Usher syndrome type IB, Usher syndrome type IIA, mucopolysaccharidosis type IIIA, mucopolysaccharidosis type IIIB, Gaucher disease type III, mucopolysaccharidosis type II, type II diabetes mellitus, type IV mucopolysaccharidosis, type I Gaucher disease, type I mucopolysaccharidosis, type I diabetes mellitus, type I Usher syndrome, KCNQ2 epileptic encephalopathy, Leber hereditary optic neuropathy, Leighsyndrome, Prader-Willi syndrome, SLC13A5 deficiency, X-linked myotubular myopathy, X-linked retinoschisis, X-linked retinitis pigmentosa, alpha-1 antitrypsin deficiency, alpha-mannosidosis, alpha-thalassemia, beta-thalassemia, Alzheimer's disease, Budd-Bieder syndrome, albicans punctata, leukocyte adhesion deficiency type I, galactosemia, bladder cancer, overactive bladder, phenylketonuria, nasopharyngeal carcinoma, Bietti's crystal dystrophy, pyruvate kinase deficiency, erectile dysfunction, autosomal dominant Recessive congenital ichthyosis, adult glucan body disease, traumatic arthritis, homozygous familial hypercholesterolemia, fragile X syndrome, thalassemia, hypophosphatasia, epilepsy, multiple myeloma, multiple system atrophy, frontotemporal dementia, catecholamine-sensitive polymorphic ventricular tachycardia, Fabry disease, Fanconi anemia, aromatic amino acid decarboxylase deficiency, radiation-induced xerostomia, non-Hodgkin lymphoma, non-muscle invasive bladder cancer, non-alcoholic fatty liver disease, non-small cell lung cancer, hypertrophic cardiomyopathy, hypertrophic scars, obesity, Charcot-Marie-Tooth disease type 1A, Charcot-Marie-Tooth disease type 2A, pulmonary hypertension, Friedreich's ataxia, peritoneal cancer, liver cancer, hepatocellular carcinoma, dry age-related macular degeneration, Sjögren's syndrome, hyperuricemia, hyperlipidemia, Gaucher disease, autism spectrum disorder, osteoarthritis, bone marrow failure syndrome, citrullinemia type 1, coronary artery disease, cystinosis, melanoma, Huntington's disease, amyotrophic lateral sclerosis, urge urinary incontinence, acute intermittent porphyria, acute lymphoblastic leukemia, spinocerebellar ataxia, spinal muscular atrophy with respiratory distress syndrome type 1, spinal muscular atrophy, tay-Sachs disease, methylmalonic acid Hypertension, thyroid cancer, pseudohypertrophic muscular dystrophy, anaplastic astrocytoma, intermittent claudication, junctional epidermolysis bullosa, glioma, glioblastoma, corneal transplant rejection, colorectal cancer, progressive multifocal leukoencephalopathy, progressive familial intrahepatic cholestasis, giant axonal neuropathy, Canavan disease, cocaine addiction, Krabbe disease, Crigler-Najjar syndrome, oral cancer, happy puppet syndrome, diffuse intrinsic pontine glioma, Lafora disease, rheumatoid arthritis, sickle cell disease, lymphedema, ovarian cancer, chronic lymphocytic leukemia, chronic granulomatous disease, Anemia in chronic kidney disease, chronic pain, chronic hepatitis B, Menkes disease, cystic fibrosis, Netherton syndrome, ornithine transcarbamylase deficiency, Parkinson's disease, Pompe disease, uveitis, prostate cancer, vestibular schwannoma, myotonic dystrophy, ankylosing spondylitis, castration-resistant prostate cancer, glaucoma, achromatopsia, ischemic heart failure, lysosomal storage disease, sarcoma, breast cancer, Rett syndrome, triple-negative breast cancer, Sandhoff disease, color blindness, heart failure with reduced ejection fraction, neuronal ceroid lipofuscinosis, adrenoleukodystrophy, renal cell carcinoma, wet age-related macular degeneration, eczema, thrombocytopenia with immunodeficiency syndrome, esophageal cancer, optic neuropathy, optic atrophy, retinal vein occlusion, retinitis pigmentosa, rhodopsin-mediated autosomal dominant retinitis pigmentosa, ependymoma, fallopian tube cancer, bilateral vestibulopathy, Stargardt's disease, diabetic macular edema, diabetic neuropathy, diabetic retinopathy, diabetic peripheral neuropathy, diabetic foot, glycogen storage disease, glycogen storage disease type Ia, glycogen storage disease type IIb, atopic dermatitis, hearing loss, hearing impairment, head and neck cancer, head and neck squamous cell carcinoma, Wilson's disease, Stable angina pectoris, Usher syndrome, choroideremia, congenital amaurosis, congenital adrenal hyperplasia, cardiomyopathy, angina pectoris, heart failure, novel coronavirus infection, pleural mesothelioma, acne vulgaris, severe combined immunodeficiency disease, severe limb ischemia, oculopharyngeal muscular dystrophy, pancreatic cancer, graft-versus-host disease, hereditary retinal dystrophy, hereditary angioedema, hepatitis B, metachromatic leukodystrophy, psoriatic arthritis, recessive dystrophic epidermolysis bullosa, infantile malignant osteosclerosis, dystrophic epidermolysis bullosa, morphea, Primary immunodeficiency, heterozygous familial hypercholesterolemia, limb-girdle muscular dystrophy type 2B, limb-girdle muscular dystrophy type 2C, limb-girdle muscular dystrophy type 2D, limb-girdle muscular dystrophy type 2E, limb-girdle muscular dystrophy type 2I, limb-girdle muscular dystrophy type 2L, limb ischemic disease, lipoprotein lipase deficiency, severe congenital neutropenia, wrinkles, stroke, sciatica, schizophrenia, depression, drug addiction, autism, idiopathic pulmonary fibrosis, transthyretin (ATTR) amyloidosis, AATD liver disease, and AATD lung disease.

7. A vector system, characterized in that The vector system comprises one or more recombinant vectors, and the recombinant vector comprises the isolated nucleic acid according to claim 5, or the CRISPR-Cas protein system according to claim 6. Optionally, the recombinant vector further comprises a regulatory sequence; Optionally, the polynucleotide sequence encoding the Cas protein, the inactivated variant of the Cas protein, the fusion protein or the conjugate is operably linked to a regulatory sequence, and / or the polynucleotide sequence encoding the guide polynucleotide is operably linked to a regulatory sequence; more preferably, the regulatory sequence is selected from one or more of a promoter, an enhancer, an internal ribosome entry site and a transcription termination signal, the promoter being, for example, a constitutive promoter, an inducible promoter, a broad-spectrum promoter, or a transcriptional termination signal. A promoter or tissue-specific promoter, and / or a transcription termination signal such as a polyadenylation signal or a poly-U sequence; Optionally, the backbone of the recombinant vector is an adeno-associated viral vector, a lentiviral vector, a ribonucleoprotein complex or a virus-like particle; preferably, when the backbone is an adeno-associated viral vector, the adeno-associated viral vector is a recombinant adeno-associated viral vector of serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12 or AAV13; when the backbone is a lentiviral vector, the lentiviral vector is pseudotyped with an envelope protein; Optionally, the isolated nucleic acid is ligated to an aptamer sequence; When the backbone of the recombinant vector is a virus-like particle, the isolated nucleic acid is connected to the gene encoding the gag protein.

8. A delivery system, characterized in that The delivery system comprises: (1) the means of delivery, and (2) the Cas protein of claim 1, the guide polynucleotide of claim 2, the inactivated variant of the Cas protein of claim 3, the fusion protein or conjugate of claim 4, the nucleic acid of claim 5, the CRISPR-Cas protein system of claim 6, or the vector system of claim 7; Optionally, the delivery vehicle is a virus, lipid nanoparticle, nanoparticle, liposome, exosome, microbubble or gene gun; Optionally, the delivery vehicle is a lipid nanoparticle comprising the guide polynucleotide and mRNA encoding the Cas protein, the inactivated variant of the Cas protein, or the fusion protein or conjugate.

9. A cell, characterized in that The cell comprises the Cas protein of claim 1 , the guide polynucleotide of claim 2 , the inactivated variant of the Cas protein of claim 3 , the fusion protein or conjugate of claim 4 , the nucleic acid of claim 5 , the CRISPR-Cas protein system of claim 6 , the vector system of claim 7 , or the delivery system of claim 8 ; Optionally, the cell is a prokaryotic cell; Optionally, the cell is a eukaryotic cell; Optionally, the eukaryotic cell is a mammalian cell.

10. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the Cas protein of claim 1, the guide polynucleotide of claim 2, the inactivated variant of the Cas protein of claim 3, the fusion protein or conjugate of claim 4, the nucleic acid of claim 5, the CRISPR-Cas protein system of claim 6, the vector system of claim 7, the delivery system of claim 8, or the cell of claim 9; Preferably, the pharmaceutical composition comprises pharmaceutically acceptable excipients.

11. A kit, characterized in that The kit comprises the Cas protein of claim 1, the guide polynucleotide of claim 2, the Cas protein inactivated variant of claim 3, the fusion protein or conjugate of claim 4, the nucleic acid of claim 5, the CRISPR-Cas protein system of claim 6, the vector system of claim 7, the delivery system of claim 8, the cell of claim 9 or the pharmaceutical composition of claim 10.

12. Use of the Cas protein according to claim 1, the guide polynucleotide according to claim 2, the inactivated variant of the Cas protein according to claim 3, the fusion protein or conjugate according to claim 4, the nucleic acid according to claim 5, the CRISPR-Cas protein system according to claim 6, the vector system according to claim 7, the delivery system according to claim 8, the cell according to claim 9, the pharmaceutical composition according to claim 10 or the kit according to claim 11 in the preparation of an agent or drug for diagnosing, treating and / or preventing a disease or disorder associated with a target nucleic acid; Optionally, the disease or condition is a blood disease or condition, an ophthalmic disease or condition, a nervous system disease or condition, a respiratory system disease or condition, a liver disease or condition, a metabolic system disease or condition, cancer or an infectious disease; and / or, the agent or drug is used to: cut one or more target nucleic acid molecules or cause a nick in one or more target nucleic acid molecules, activate or upregulate the expression of one or more target nucleic acid molecules, activate or inhibit the transcription of one or more target nucleic acid molecules, inactivate one or more target nucleic acid molecules, visualize, label or detect one or more target nucleic acid molecules, bind one or more target nucleic acid molecules, transport one or more target nucleic acid molecules, and mask one or more target nucleic acid molecules; Further optionally, the disease or condition is selected from: hemophilia A, Best vitelliform macular dystrophy, B-cell acute lymphoblastic leukemia, hemophilia B, CDKL5 deficiency, CLN2 disease, Niemann-Pick disease type C, Dravet syndrome, FOXG1 syndrome, GM1 gangliosidosis, GM2 gangliosidosis, HIV infection, HSV infection, Usher syndrome type IB, Usher syndrome type IIA, mucopolysaccharidosis type IIIA, mucopolysaccharidosis type IIIB, Gaucher disease type III, mucopolysaccharidosis type II, type II diabetes, mucopolysaccharidosis type IV, Gaucher disease type I, mucopolysaccharidosis type I, type I diabetes, Usher syndrome type I, KCNQ2 epileptic encephalopathy, Leber hereditary optic neuropathy, Leigh syndrome, Prader-Willi syndrome, SLC13A5 deficiency, X-linked myotubular myopathy, X-linked retinoschisis, X-linked retinitis pigmentosa, alpha-1 antitrypsin deficiency, alpha-mannosidosis, alpha-thalassemia, beta-thalassemia, Alzheimer's disease, Bardet-Biedl syndrome group, albicans retinal degeneration, leukocyte adhesion deficiency type I, galactosemia, bladder cancer, overactive bladder, phenylketonuria, nasopharyngeal carcinoma, Bietti crystal dystrophy, pyruvate kinase deficiency, erectile dysfunction, autosomal recessive congenital ichthyosis, adult glucan body disease, traumatic arthritis, homozygous familial hypercholesterolemia, fragile X syndrome, thalassemia, hypophosphatasia, epilepsy, multiple myeloma, multiple system atrophy, frontotemporal dementia, catecholamine-sensitive polymorphic ventricular tachycardia, Fabry disease, Fanconi anemia, aromatic amino acid decarboxylase deficiency, radiation-induced xerostomia, non-Hodgkin lymphoma, non-muscle invasive bladder cancer, non-alcoholic fatty liver disease, non-small cell lung cancer Lung cancer, hypertrophic cardiomyopathy, hypertrophic scarring, obesity, Charcot-Marie-Tooth disease type 1A, Charcot-Marie-Tooth disease type 2A, pulmonary hypertension, Friedreich's ataxia, peritoneal cancer, liver cancer, hepatocellular carcinoma, dry age-related macular degeneration, Sjögren's syndrome, hyperuricemia, hyperlipidemia, Gaucher disease, autism spectrum disorder, osteoarthritis, bone marrow failure syndrome, citrullinemia type 1, coronary artery disease, cystinosis, melanoma, Huntington's disease, amyotrophic lateral sclerosis, urge urinary incontinence, acute intermittent porphyria, acute lymphoblastic leukemia, spinocerebellar ataxia, spinal muscular atrophy with respiratory distress syndrome type 1, spinal muscular atrophy, familial Tay-Sachs disease, methylmalonic acidemia, thyroid cancer, pseudohypertrophic muscular dystrophy, anaplastic anemia Astrocytoma, intermittent claudication, junctional epidermolysis bullosa, glioma, glioblastoma, corneal transplant rejection, colorectal cancer, progressive multifocal leukoencephalopathy, progressive familial intrahepatic cholestasis, giant axonal neuropathy, Canavan disease, cocaine addiction, Krabbe disease, Crigler-Najjar syndrome, oral cancer, Happy Marionette syndrome, diffuse intrinsic pontine glioma, Lafora disease, rheumatoid arthritis, sickle cell disease, lymphedema, ovarian cancer, chronic lymphocytic leukemia, chronic granulomatous disease, anemia of chronic kidney disease, chronic pain, chronic hepatitis B, Menkes disease, cystic fibrosis, Netherton syndrome, ornithine transcarbamylase deficiency, Parkinson's disease, Pompe disease, uveitis, prostate cancer, vestibular nerve Sheath tumor, myotonic dystrophy, ankylosing spondylitis, castration-resistant prostate cancer, glaucoma, achromatopsia, ischemic heart failure, lysosomal storage disease, sarcoma, breast cancer, Rett syndrome, triple-negative breast cancer, Sandhoff disease, color blindness, heart failure with reduced ejection fraction, neuronal ceroid lipofuscinosis, adrenoleukodystrophy, renal cell carcinoma, wet age-related macular degeneration, eczema, thrombocytopenia with immunodeficiency syndrome, esophageal cancer, optic neuropathy, optic atrophy, retinal vein occlusion, retinitis pigmentosa, rhodopsin-mediated autosomal dominant retinitis pigmentosa, ependymoma, fallopian tube cancer, bilateral vestibulopathy, Stargardt's disease, diabetic macular edema, diabetic neuropathy, diabetic retinopathy,Diabetic peripheral neuropathy, diabetic foot, glycogen storage disease, glycogen storage disease type Ia, glycogen storage disease type IIb, atopic dermatitis, hearing loss, hearing impairment, head and neck cancer, head and neck squamous cell carcinoma, Wilson's disease, stable angina, Usher syndrome, choroideremia, congenital amaurosis, congenital adrenal hyperplasia, cardiomyopathy, angina pectoris, heart failure, new coronavirus infection, pleural mesothelioma, acne vulgaris, severe combined immunodeficiency, severe limb ischemia, oculopharyngeal muscular dystrophy, benign prostatic hyperplasia (BPH), pancreatic cancer, graft-versus-host disease, hereditary retinal dystrophy, hereditary angioedema, hepatitis B, metachromatic leukodystrophy, psoriatic arthritis, recessive dystrophic epidermolysis bullosa, infantile malignant osteosclerosis, dystrophic epidermolysis bullosa, morphea, primary immunodeficiency, heterozygous familial hypercholesterolemia, limb-girdle muscular dystrophy type 2B, limb-girdle muscular dystrophy type 2C, limb-girdle muscular dystrophy type 2D, limb-girdle muscular dystrophy type 2E, limb-girdle muscular dystrophy type 2I, limb-girdle muscular dystrophy type 2L, limb ischemic disease, lipoprotein lipase deficiency, severe congenital neutropenia, wrinkles, stroke, sciatica, schizophrenia, depression, drug addiction, autism, idiopathic pulmonary fibrosis, transthyretin (ATTR) amyloidosis, AATD liver disease, and AATD lung disease.

13. A method for detecting, binding or cleaving a target nucleic acid, characterized in that: The method comprises contacting a target nucleic acid with the Cas protein of claim 1 , the guide polynucleotide of claim 2 , the inactivated variant of the Cas protein of claim 3 , the fusion protein or conjugate of claim 4 , the nucleic acid of claim 5 , the CRISPR-Cas protein system of claim 6 , the vector system of claim 7 , the delivery system of claim 8 , the cell of claim 9 , the pharmaceutical composition of claim 10 , or the kit of claim 11 ; Optionally, the method is a method for non-diagnostic and / or therapeutic purposes; and / or the fusion protein or conjugate comprises a detectable label, such as a label detectable by fluorescence, Southern blotting or FISH.

14. A method for changing a cell state, characterized in that: The method comprises contacting a cell with the Cas protein of claim 1 , the guide polynucleotide of claim 2 , the inactivated variant of the Cas protein of claim 3 , the fusion protein or conjugate of claim 4 , the nucleic acid of claim 5 , the CRISPR-Cas protein system of claim 6 , the vector system of claim 7 , the delivery system of claim 8 , the cell of claim 9 , the pharmaceutical composition of claim 10 , or the kit of claim 11 , thereby changing the cell state; Optionally, the method results in one or more of: increased or decreased expression of a specific gene, induction of cellular senescence in vitro or in vivo, cell cycle arrest in vitro or in vivo, cell growth promotion and / or cell growth inhibition in vitro or in vivo, induction of anergy in vitro or in vivo, induction of apoptosis in vitro or in vivo, and induction of necrosis in vitro or in vivo; Optionally, the method is a method for non-diagnostic and / or therapeutic purposes.

15. A method for diagnosing, treating or preventing a disease or condition associated with a target nucleic acid, characterized in that: administering the Cas protein of claim 1 , the guide polynucleotide of claim 2 , the inactivated variant of the Cas protein of claim 3 , the fusion protein or conjugate of claim 4 , the nucleic acid of claim 5 , the CRISPR-Cas protein system of claim 6 , the vector system of claim 7 , the delivery system of claim 8 , the cell of claim 9 , the pharmaceutical composition of claim 10 , or the kit of claim 11 to a sample of a subject in need or to a subject in need; Preferably, the disease or disorder is a blood system disease or disorder, an eye disease or disorder, a nervous system disease or disorder, a respiratory system disease or disorder, a liver disease or disorder, a metabolic system disease or disorder, cancer or an infectious disease; More preferably, the disease or disorder is selected from the group consisting of hemophilia A, Best vitelliform macular dystrophy, B-cell acute lymphoblastic leukemia, hemophilia B, CDKL5 deficiency, CLN2 disease, Niemann-Pick disease type C, Dravet syndrome, FOXG1 syndrome, GM1 gangliosidosis, GM2 gangliosidosis, HIV infection, HSV infection, Usher syndrome type IB, Usher syndrome type IIA, mucopolysaccharidosis type IIIA, mucopolysaccharidosis type IIIB, Gaucher disease type III, mucopolysaccharidosis type II, type II diabetes, mucopolysaccharidosis type IV, Gaucher disease type I, mucopolysaccharidosis type I, type I diabetes, Usher syndrome type I, KCNQ2 epileptic encephalopathy, Leber hereditary optic neuropathy, Leigh syndrome, Prader-Willi syndrome, SLC13A5 deficiency, X-linked myotubular myopathy, X-linked retinoschisis, X-linked retinitis pigmentosa, alpha-1 antitrypsin deficiency, alpha-mannosidosis, alpha-thalassemia, beta-thalassemia, Alzheimer's disease, Budd-Bieder syndrome, albicans punctata, leukocyte adhesion deficiency type I, galactosemia, bladder cancer, overactive bladder, phenylketonuria, nasopharyngeal carcinoma, Bietti lens dystrophy benign prostatic hyperplasia (BPH), pyruvate kinase deficiency, erectile dysfunction, autosomal recessive congenital ichthyosis, adult glucan body disease, post-traumatic arthritis, homozygous familial hypercholesterolemia, fragile X syndrome, thalassemia, hypophosphatasia, epilepsy, multiple myeloma, multiple system atrophy, frontotemporal dementia, catecholamine-sensitive polymorphic ventricular tachycardia, Fabry disease, Fanconi anemia, aromatic amino acid decarboxylase deficiency, radiation-induced xerostomia, non-Hodgkin lymphoma, and non-muscle invasive bladder cancer, nonalcoholic fatty liver disease, non-small cell lung cancer, hypertrophic cardiomyopathy, hypertrophic scarring, obesity, Charcot-Marie-Tooth Disease Type 1A, Charcot-Marie-Tooth Disease Type 2A, pulmonary hypertension, Friedreich's ataxia, peritoneal cancer, liver cancer, hepatocellular carcinoma, dry age-related macular degeneration, Sjögren's syndrome, hyperuricemia, hyperlipidemia, Gaucher disease, autism spectrum disorder, osteoarthritis, bone marrow failure syndrome, citrullinemia type 1, coronary artery disease, cystinosis, melanoma, Huntington's disease, amyotrophic lateral sclerosis, urgency urination Incontinence, acute intermittent porphyria, acute lymphoblastic leukemia, spinocerebellar ataxia, spinal muscular atrophy with respiratory distress type 1, spinal muscular atrophy, familial Tay-Sachs disease, methylmalonic acidemia, thyroid cancer, pseudohypertrophic muscular dystrophy, anaplastic astrocytoma, intermittent claudication, junctional epidermolysis bullosa, glioma, glioblastoma, corneal transplant rejection, colorectal cancer, progressive multifocal leukoencephalopathy, progressive familial intrahepatic cholestasis, giant axonal neuropathy, Canavan disease, cocaine addiction Addiction, Krabbe disease, Crigler-Najjar syndrome, oral cancer, Happy Marionette syndrome, diffuse intrinsic pontine glioma, Lafora disease, rheumatoid arthritis, sickle cell disease, lymphedema, ovarian cancer, chronic lymphocytic leukemia, chronic granulomatous disease, anemia of chronic kidney disease, chronic pain, chronic hepatitis B, Menkes disease, cystic fibrosis, Netherton syndrome, ornithine transcarbamylase deficiency, Parkinson's disease, Pompe disease, uveitis, prostate cancer, vestibular schwannoma, myotonic dystrophy, ankylosing spondylitis, castration-resistant prostate cancer, glaucoma, achromatopsia, ischemic heart failure, lysosomal storage disease, sarcoma, breast cancer, Rett syndrome, triple-negative breast cancer, Sandhoff disease, color blindness, heart failure with reduced ejection fraction, neuronal ceroid lipofuscinosis, adrenoleukodystrophy, renal cell carcinoma, wet age-related macular degeneration, eczema, thrombocytopenia with immunodeficiency syndrome, esophageal cancer, optic neuropathy, optic atrophy, retinal vein occlusion, retinitis pigmentosa, rhodopsin-mediated autosomal dominant retinitis pigmentosa, ependymoma, fallopian tube cancer, bilateral vestibulopathy, Stargardt disease, diabetic macular edema, diabetic neuropathy, diabetic retinopathy, diabetic peripheral neuropathy, diabetic foot, glycogen storage disease, glycogen storage disease type Ia , glycogen storage disease type IIb, atopic dermatitis, hearing loss, hearing impairment, head and neck cancer, head and neck squamous cell carcinoma, Wilson's disease, stable angina pectoris, Usher syndrome, choroideremia, congenital amaurosis, congenital adrenal hyperplasia, cardiomyopathy, angina pectoris, heart failure, new coronavirus infection, pleural mesothelioma, acne vulgaris, severe combined immunodeficiency disease, severe limb ischemia, oculopharyngeal muscular dystrophy, pancreatic cancer, graft-versus-host disease, hereditary retinal dystrophy, hereditary angioedema, hepatitis B, metachromatic leukodystrophy, psoriatic arthritis, recessive hereditary dystrophic epidermolysis bullosa, infantile malignancy osteopetrosis, dystrophic epidermolysis bullosa, morphea, primary immunodeficiency, heterozygous familial hypercholesterolemia, limb-girdle muscular dystrophy type 2B, limb-girdle muscular dystrophy type 2C, limb-girdle muscular dystrophy type 2D, limb-girdle muscular dystrophy type 2E, limb-girdle muscular dystrophy type 2I, limb-girdle muscular dystrophy type 2L, limb ischemic disease, lipoprotein lipase deficiency, severe congenital neutropenia, wrinkles, stroke, sciatica, schizophrenia, depression, drug addiction, autism, idiopathic pulmonary fibrosis, transthyretin (ATTR) amyloidosis, AATD liver disease, and AATD lung disease.

16. The Cas protein of claim 1, the guide polynucleotide of claim 2, the inactivated variant of the Cas protein of claim 3, the fusion protein or conjugate of claim 4, the nucleic acid of claim 5, the CRISPR-Cas protein system of claim 6, the vector system of claim 7, the delivery system of claim 8, the cell of claim 9, the pharmaceutical composition of claim 10 or the kit of claim 11, for use in diagnosing, treating or preventing a disease or disorder associated with a target nucleic acid; Preferably, the disease or condition is a blood system disease or condition, an eye disease or condition, a nervous system disease or condition or condition, respiratory disease or condition, liver disease or condition, metabolic disease or condition, cancer or infectious disease; More preferably, the disease or disorder is selected from the group consisting of hemophilia A, Best vitelliform macular dystrophy, B-cell acute lymphoblastic leukemia, hemophilia B, CDKL5 deficiency, CLN2 disease, Niemann-Pick disease type C, Dravet syndrome, FOXG1 syndrome, GM1 gangliosidosis, GM2 gangliosidosis, HIV infection, HSV infection, Usher syndrome type IB, Usher syndrome type IIA, mucopolysaccharidosis type IIIA, mucopolysaccharidosis type IIIB, Gaucher disease type III, mucopolysaccharidosis type II, type II diabetes, mucopolysaccharidosis type IV, Gaucher disease type I, mucopolysaccharidosis type I, type I diabetes, Usher syndrome type I, KCNQ2 epileptic encephalopathy, Leber hereditary optic neuropathy, Leighsyndrome, Prader-Willi syndrome, SLC13A5 deficiency, X-linked myotubular myopathy, X-linked retinoschisis, X-linked retinitis pigmentosa, alpha-1 antitrypsin deficiency, alpha-mannosidosis, alpha-thalassemia, beta-thalassemia, Alzheimer's disease, Budd-Bieder syndrome, albicans punctata, leukocyte adhesion deficiency type I, galactosemia, bladder cancer, overactive bladder, phenylketonuria, nasopharyngeal carcinoma, Bietti's crystal dystrophy, pyruvate kinase deficiency, erectile dysfunction, autosomal recessive congenital ichthyosis, adult glucanosis Disease, traumatic arthritis, homozygous familial hypercholesterolemia, fragile X syndrome, thalassemia, hypophosphatasia, epilepsy, multiple myeloma, multiple system atrophy, frontotemporal dementia, catecholamine-sensitive polymorphic ventricular tachycardia, Fabry disease, Fanconi anemia, aromatic amino acid decarboxylase deficiency, radiation-induced xerostomia, non-Hodgkin lymphoma, non-muscle-invasive bladder cancer, non-alcoholic fatty liver disease, non-small cell lung cancer, hypertrophic cardiomyopathy, hypertrophic scars, obesity, Charcot-Marie-Tooth Disease Type 1A, Charcot-Marie-Tooth Disease Type 2A, pulmonary hypertension, Friedrich's ataxia, peritoneal cancer, liver cancer, liver Cell carcinoma, dry age-related macular degeneration, Sjögren's syndrome, hyperuricemia, hyperlipidemia, Gaucher disease, autism spectrum disorder, osteoarthritis, bone marrow failure syndrome, citrullinemia type I, coronary heart disease, cystinosis, melanoma, Huntington's disease, amyotrophic lateral sclerosis, urge urinary incontinence, acute intermittent porphyria, acute lymphoblastic leukemia, spinocerebellar ataxia, spinal muscular atrophy with respiratory distress type 1, spinal muscular atrophy, familial dementia, methylmalonic acidemia, thyroid cancer, pseudohypertrophic muscular dystrophy, anaplastic astrocytoma, intermittent claudication, junctional epidermolysis bullosa, glioma, Glioblastoma, corneal transplant rejection, colorectal cancer, progressive multifocal leukoencephalopathy, progressive familial intrahepatic cholestasis, giant axonal neuropathy, Canavan disease, cocaine addiction, Krabbe disease, Crigler-Najjar syndrome, oral cancer, Happy Marionette syndrome, diffuse intrinsic pontine glioma, Lafora disease, rheumatoid arthritis, sickle cell disease, lymphedema, ovarian cancer, chronic lymphocytic leukemia, chronic granulomatous disease, anemia of chronic kidney disease, chronic pain, chronic hepatitis B, Menkes disease, cystic fibrosis, Netherton syndrome, ornithine transcarbamylase deficiency, Parkinson's disease, Pompe disease, uveitis, prostate Cancer, vestibular schwannoma, myotonic dystrophy, ankylosing spondylitis, castration-resistant prostate cancer, glaucoma, achromatopsia, ischemic heart failure, lysosomal storage disease, sarcoma, breast cancer, Rett syndrome, triple-negative breast cancer, Sandhoff disease, color blindness, heart failure with reduced ejection fraction, neuronal ceroid lipofuscinosis, adrenoleukodystrophy, renal cell carcinoma, wet age-related macular degeneration, eczema, thrombocytopenia with immunodeficiency syndrome, esophageal cancer, optic neuropathy, optic atrophy, retinal vein occlusion, retinal Pigmentary degeneration, rhodopsin-mediated autosomal dominant retinitis pigmentosa, ependymoma, fallopian tube cancer, bilateral vestibulopathy, Stargardt's disease, diabetic macular edema, diabetic neuropathy, diabetic retinopathy, diabetic peripheral neuropathy, diabetic foot, glycogen storage disease, glycogen storage disease type Ia, glycogen storage disease type IIb, atopic dermatitis, hearing loss, hearing impairment, head and neck cancer, head and neck squamous cell carcinoma, Wilson's disease, stable angina, Ussher syndrome, choroideremia, congenital amaurosis, congenital adrenal Cortical hyperplasia, cardiomyopathy, angina pectoris, heart failure, novel coronavirus infection, pleural mesothelioma, acne vulgaris, severe combined immunodeficiency, severe limb ischemia, oculopharyngeal muscular dystrophy, pancreatic cancer, graft-versus-host disease, hereditary retinal dystrophy, hereditary angioedema, hepatitis B, metachromatic leukodystrophy, psoriatic arthritis, recessive dystrophic epidermolysis bullosa, infantile malignant osteosclerosis, dystrophic epidermolysis bullosa, morphea, primary immunodeficiency, heterozygous familial hypertrophic Cholesterolemia, limb-girdle muscular dystrophy type 2B, limb-girdle muscular dystrophy type 2C, limb-girdle muscular dystrophy type 2D, limb-girdle muscular dystrophy type 2E, limb-girdle muscular dystrophy type 2I, limb-girdle muscular dystrophy type 2L, limb ischemic disease, lipoprotein lipase deficiency, severe congenital neutropenia, wrinkles, stroke, sciatica, schizophrenia, depression, drug addiction, autism, idiopathic pulmonary fibrosis, transthyretin (ATTR) amyloidosis, AATD liver disease, and AATD lung disease.

Citation Information

Patent Citations

  • Novel CRISPR DNA targeting enzyme and system

    CN114729011A

  • Novel Cas effector proteins, gene editing systems and their applications

    CN114934031A

  • Cas9 protein, gene editing system containing Cas9 protein and application

    CN116144629A

  • Cas protein, corresponding gene editing system and application thereof

    CN117165557A

  • Cas13 protein and application thereof

    CN117230043A